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ABSTRACT 
Antimicrobial Properties of Syringopeptin 25A and Rhamnolipids 
by 
Prerak T. Desai , Master of Science 
Utah State University , 2005 
Major Professor : Dr. Bart C. Weimer 
Department: Nutrition and Food Sciences 
111 
The increasing bacterial resistance to available antibiotics requires the search for 
new antibacterial compounds to be broadened. This study investigated the antimicrobial 
properties of two secondary metabolites from fluorescent pseudo monads -- syringopeptin 
25A, a lipodepsipeptide produced by Pseudomonas syringae pv . syringae , and a 
rhamnolipid mixture produced by Pseudomonas aeruginosa. The rate of antimicrobial 
action was determined by monitoring the rate of uptake of propidium iodide during 
exposure to the compounds . Inhibition was also confirmed by the microbroth dilution 
method to determine the MI Cs. Both the compounds inhibited growth of Gram-positive 
organisms, including Mycobacterium smegmatis , staphylococci, and listeria. Inhibition 
of spore germination was also notable. SP 25A inhibited two multiple antibiotic strains of 
Staphylococcus aureus subsp. aureus and Enterococcus faecalis , while RLs failed to do 
IV 
so, even at 60 µg/ml. Addition of the compounds together showed a synergistic activity 
against Listeria monocytogenes. Neither compound was toxic to human cells in vitro at 8 
µg/ml. 
It is postulated that both compounds exert their antimicrobial effect by forming 
pores in the bacterial cell membrane, but we did not observe a relation between 
membrane permeabilization and inhibition of growth in each case . At sub-MIC 
concentrations RLs did cause pores in the membrane of L. monocytogenes , while SP 25A 
did not. However , RLs did not inhibit cell growth , while SP 25A completely inhibited 
cell growth . 
To investigate these effects gene expression was monitored just before treating 
the cells with the antimicrobials , 30 min after treatment and 120 min after treatment. The 
gene expression profile was distinct when cells were treated with both the antimicrobials. 
SP 25A repressed genes related to cell division, intermediary metabolism, transcription , 
translation, and virulence genes. These effects were not produced when cells were treated 
with RLs, hence giving indications that even though both the antimicrobials may act on 
the same site (i.e. the cell membrane), the cellular response was different, which led to 
different phenotypes for growth. 
This work indicates that SP 25A holds promise for further development as a 
therapeutic agent and provides evidence that the proposed pore-forming model alone 
does not suffice to explain the mode of action of SP 25A. 
(105 pages) 
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CHAPTER 1 
INTRODUCTION 
Very few developments in the history of health science have had such a profound 
impact upon human life as the advances in controlling pathogenic microorganisms since 
the discovery of penicillin. Though the application of antimicrobial agents preceded the 
understanding of their action , it was not until the late 19th and early 20th century that the 
work of Pasteur and Koch firmly established that microorganisms as the cause of 
infectious diseases and provided strategies that led to rational prevention and control 
strategies . The first group of compounds discovered to suppress bacterial infections were 
sulphonamides (2) . The success of sulphonamides along with the world wars stimulated a 
massive hunt for more effective antimicrobials . Florey and Chain (3) succeeded in 
isolating an impure but highly active preparation of penicillin and published their results 
in 1940. The enormous success of penicillin quickly diverted a great deal of scientific 
effort towards search of other antibiotics that culminated in the discovery or 
approximately 3,000 named antibiotics. Of these, 50 have met with clinical use and many 
fewer are regularly employed in therapy of infectious diseases (2). 
The initial success of those antibiotics is now marred with emergence of resistant 
organisms. Antibiotic resistance is a complex problem accelerated by the versatility of 
the microbes, overuse of antibiotics, and the lack of patients completing the prescribed 
dosage (1). Curable diseases such as gonorrhoeae and typhoid are becoming difficult to 
treat ( 4) due to resistance issues. However , the most troubling issue is the establishment 
of vancomycin resistant organisms ( 4) . The solution to the problem of antimicrobial 
resistance is very complex and a tough scientific issue. The primary path forward for 
keeping infectious agents at bay is to continuously discover new antimicrobial 
compounds. This path becomes easier if we better understand the mode of resistance and 
susceptibility . With the advances in genomics, this task become should become easier 
and faster. The knowledge obtained from system-wide genome analysis will help us in 
designing better molecules to inhibit microbes in multiple modes. 
References: 
1. Ang, J. Y., E. Ezike, and B. I. Asmar. 2004. Antibacterial resistance. Indian 
J.Pediatr. 71:229-39. 
2. Hammond S. M., P.A. L. 1978. Antibiotic resistance in microorganisms. In, 
Antibiotics and antimicrobial action , E Arnold London . Chapter 8 :53-63 
3. Ligon, B. L. 2004. Sir Howard Walter Florey--the force behind the development 
of penicillin . Semin. Pediatr. Infect. Dis. 15: 109-14. 
4 . Richet, H. M., J. Mohammed, L. C. McDonald, and W.R. Jarvis. 2001. 
Building communication networks: international network for the study and 
prevention of emerging antimicrobial resistance. Emerg. Infect. Dis. 7:319-22. 
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CHAPTER2 
LITERATURE REVIEW 
Molecular mechanisms of antibiotic action 
The word antibiotic brings together a varied group of compounds with little in 
common except for their antimicrobial activity. Hence , it is not surprising that they 
prevent the growth of susceptible bacteria by different molecular mechanisms . The five 
major mechanisms by which the antibiotics attack bacterial cells are (25, 35, 40) : 
1. Blocking steps in cell wall synthesis. This group is exemplified by penicillin , 
cephalosporin, cycloserine , and vancomycin. These antibiotics interfere with the 
biosynthesis of peptidoglycan and damage its cross linked macromolecular structur e 
which can arrest growth and kill the bacteria. 
2. Permeabilizing cell membrane. Polymyxin , tyrocidin , and va linomycin are examples 
of this mode of action. When cells are treated with lethal doses of these antibiotics 
they interact with the components of cell membrane , probably proteins , and induce a 
lesion in the cell membrane hence impairing its ability to act as a semi permeable 
barrier between the cell and its environment causing the cell components to leak out. 
3. Inhibition of nucleic acid function. This group has examples including rifampicin , 
actinomycin D, and acridines . These compounds interfere at various stages 
(nucleotide biosynthesis, polymerization of nucleotides) of DNA replication and 
ultimatel y cause loss of gene expression , which is fatal to bacterial cells . 
3 
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4. Inhibition ofprotein synthesis. For example streptomycin, tetracyclines , and 
chloramphenicol are used that act in this mode. These compounds bind the subunits 
of ribosome and distort the ribosome enough to prevent normal codon anticodon 
interaction leading to either inhibition of protein synthesis or faulty protein synthesis. 
5. Inhibition of cellular metabolism. This is exemplified by sulphonamides. These 
compounds inhibit the synthesis of folic acid by competing with p-amino benzoic 
acid as a substrate for enzyme tetrahydropteroic acid synthetases that incorporates p-
amino benzoic acid into the folic acid molecule . 
Antibiotic resistance in microorganisms 
The development of microbial strains that are resistant to antibiotics is 
unfortunately an ever increasingly common phenomenon . Antibiotic resistance may be 
divided into two categories: 
Intrinsic resistance: Generally Gram-negative bacteria are more resistant to 
antibiotics than Gram-positive bacteria (4, 17, 35). This greater intrinsic resistance of 
Gram-negative bacteria to antimicrobial agents may depend upon the nonspecific 
permeability barrier presented by the outer membrane , preventing access of the antibiotic 
molecules to their active site ( 4, 17, 35). Some bacteria may be inherently resistant due 
to presence of various defense mechanisms like presence of antibiotic degrading 
enzymes, presence of antibiotic efflux mechanisms or the organism may altogether lack 
the drug target (4, 17, 35). 
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Acquired resistance: Overuse of antibiotics and consequent antibiotic selective 
pressure is thought to be the most important factor contributing to the organisms gaining 
antibiotic resistance (4, 17, 25, 35, 39). Mechanisms by which the microbes gain 
resistance may be due to spontaneo us mutations , transduction, transposons or conjugation 
(25) . Bernard Davis (1952) first outlined the possible biochemical mechanisms of drug 
resistance. They may be swnmarized as follows (4, 17, 35): 
1. Conversion of an active drug to an inactive derivative ( e.g. inactivation of P-lactam 
antibiotics by P-lactamases) . 
2. Enhancement of alternative metabolic pathways (e.g. the pathways responsible for the 
salvage of purin e and pyrimidine bases from nucleic acid catabolism) ; thereby 
allowing their reutilization into new nucleic acids . This may be used to circumvent 
the antibacterial activity of certain nucleic acid analogues. 
3. Reduction in physiological importance of the target site, for e.g. bacteria may 
overcome the antimicrobial action of sulphonamides by accumulating large amounts 
of PABA (Para amino benzoic acid) . 
4. Loss of cell permeability to a drug due to synthesis of an additional permeability 
barrier (if the antibiotic gains access through passive transport) or due to loss of a 
specific transport mechanism (i.e. if the antibiotic gains access through a particular 
transport mechanism). 
5. Modification of the antibiotic sensitive site ( e.g. resistance to erythromycin in several 
bacterial species depends on an alteration in a protein of the SOS ribosome subunit 
that leads to a reduced affinity of ribosomes for erythromycin). 
6. Active efflux of the antibiotic from the cytoplasm ( e.g. resistance to tetracycline in 
several Gram-positive as well as Gram-negative bacteria depends upon an ATP 
dependent efflux system present in the cytoplasmic membrane). 
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Antibiotic resistance is a global health problem and is increasing . With every new 
antimicrobial compound discovered or synthesized we are only a step ahead of microbes 
before they become resistant. Recent increases in bacterial and fungal infections , the few 
available antibiotics and the increasing resistance to the available antibiotics have 
resulted in a broadening of the search for new inhibitory compounds . 
Secondary metabolites from pseudomonads 
as potential antimicrobials 
Secondary metabolites from microbes are compounds produced and typically 
secreted into the environment during the stationary phase of growth , and so are not 
produced or required for growth (12, 30) . The physiology of stationary phase cells is 
adapted to restricted nutrients or another nutritional change, which allows the cell to shift 
metabolism leading to the production of these compounds. One can think of this phase as 
an environmental stress that result in changes in cellular metabolism that induces the 
production of new compounds that are known as secondary metabolites. Often these 
secondary metabolites are directed at inhibiting competing organisms that occupy the 
same niche to give the producing organism a selective advantage . There are two ways to 
increase ones competitive fitness in a 'tight' environment: self-improvement (increasing 
ones own ability to gather nutrients) , or by decreasing the fitness of ones competitors. 
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Siderophores and high-affinity nutrient uptake mechanisms are examples of how a cell 
can increase its supply of nutrients (12, 30). Antibiotics and bacteriocins are examples of 
how an organism can increase its supply of nutrients by crippling its competition (6, 12, 
30). 
Pseudomonads produce a variety of secondary metabolites that act as phytotoxins 
or antimicrobial/antifungal agents (6, 12, 30) (Table 2.1 ).Pseudomonads produce a wide 
spectrum of chemically distinct and biologically active compounds that inhibit other 
microbes. Among the most well characterized compounds are those produced by plant 
pathogen Pseudomonas syringae and opportunistic pathogen Pseudomonas aeruginosa . 
This study would be focusing on two compounds; syringopeptins produced by P. 
syringae pv . syringae and rhamnolipids produced by P. aeruginosa owing to very 
promising results obtained in the preliminary studies. 
Syringopeptins 
Syringopeptins (SPs) are a class of cyclic peptides substituted with fatty acids 
known as cyclic lipodepsipeptides that are produced by several strains of P. syringae pv . 
syringae. Currently , five different syringopeptins have been identified that vary in their 
fatty acid chain length and number and composition of amino acids in the peptide moiety 
(2, 3, 6, 13, 15, 16, 19, 23, 43). Syringopeptins contain either 22 or 25 amino acids 
depending upon the specific bacterial strain from which it was purified. Often the N-
terminal (2, 3-dehydro-2-aminobutyric acid) is acylated with either 3-hydroxydecanoic or 
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3-hydroxydodecanoic acid (5, 6, 24). An eight-member lactone ring is formed due to the 
ester bond between allothreonine and C-terminal tyrosine (5, 6, 24). A high percentage of 
hydrophobic amino acids are found in syringopeptins and it has been determined that the 
peptide moiety is primarily composed of D-amino acids (5, 6, 24). The peptide sequence 
of the syringopeptins may vary from strain to strain (5, 6, 24). 
The conformation is characterized by three structural regions: 1) a loop including 
the residues from Pro2 to Val6, 2) a helicoidal zone including the residues from Ala8 to 
Alal 5, and 3) the lactone ring including Thrl 8 to Tyr25. This three-dimensional 
conformation likely leads to changes in the membrane environment as discussed later in 
this review (31) (Fig . 2.2) . Primarily , it is a phytotoxin and functions as a virulence factor 
for P. syringae by playing a major role in inducing necrosis in plant cells (6). Studies 
with knock out mutants have shown that organisms deficient in SP production are less 
virulent, though some diseases may also occur in its absence ( 18). It has the ability to 
cause electrolyte leakage by forming pores in plant plasma membranes , thereby 
promoting transmembrane ion flux that leads to necrotic symptoms (23). It also displays 
biosurfactant properties with a critica l micelle concentration of 0.9 mM for SP 25A and 
0.4 mM for SP 22A, which may aid in the spread of organisms on the plant surface (6, 
21). 
Though the antimicrobial properties of this compound have yet to be fully 
assessed, preliminary studies show promising results to inhibit many different bacteria. 
Initial studies found these compounds inhibit Gram-positive bacteria at micromolar 
concentrati ons, with the MIC values ranging from about 1.5 to 37 µg/ml for various 
organisms (Table 2.2) . 
Little information about the mechanism is published describing the mode of 
action of the SPs against bacteria , but the initial studies indicate that SPs form pores in 
model membranes (3, 21, 23, 31, 43). It has been predicted that the SP molecule first 
adsorbs onto the cell membrane with the hydrophobic acyl chain inserted between those 
of the phospholipids of eel l membran e, while the hydrophobic linear peptide portion and 
the hydrophilic cyclic moiety remain folded as they are in solution . Presumably , the 
adsorbed monome rs form aggregates that eventually form the pore, since more than one 
monomer is required to form a pore (14, 21) . After forming aggregate s the hydrophobic 
portion unfolds and aligns with the lipid tails spanning the membran e that causes the 
formation of a pore. This pore formation is voltage dependent as observed in plan ar lipid 
membranes (21) . Once the pore is formed , the cell would loose its permeability barrier 
and ultimately lead to cell death . 
Rhamnolipids 
Rhamnolipids (RLs) are biosurfactants produced by several strains of 
Pseudomonas aeruginosa (1, 7, 8, 12, 20, 30, 32, 33, 38). What makes these compounds 
interesting is that it also shows antimicrobial activity the potential applications of which 
could be enormous if they inhibit many types of bacteria (1, 7, 20) . RLs are often a 
mixture of various homologues , depending upon the strain and carbon source provided 
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during growth (33). Eleven different homologues have been identified in cultures of 
P. aeruginosa (20) (Fig . 2.3). The physiological role of a specific RL is not well 
understood , but since they have very good surface active properties they may: 
1. Emulsify hydrocarbons or hydrophobic substrates making them available for cell 
metabolism (28, 36). 
2. Help the cells in swarming motility under nutrient limitations (28) . 
3. Cripple the competing organisms for nutrients by the virtue of it antimicrobial 
activity (1, 7, 20). 
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4. They may play a role as a virulence factor (34). In vivo RLs prevent phagocytosis of 
the organism by macrophages by bringing about structural changes in the 
macrophages so they cannot associate with the bacteria (34). 
RLs have an array of applications due their versatility in bioactivity. A few of 
them are as follows: 
1. They are useful in bioremediation and bi ode gradation of organic compounds , both 
aliphatic and aromatic. Addition of RLs to pure cultures of bacteria increase 
biodegradation of hexadecane , octadecane, n-paraffin, phenanthrene, tetradecane , 
pristine and creosote (32) . This phenomenon could be due to their surface-active 
properties since they increase the solubility of the hydrocarbons and hence make them 
readily available to the degrading cells , or they may increase the surface 
hydrophobicity of the cells by removing lipopolysaccharides from the cell wall 
improving the association of more hydrophobic substrates with the cells (32). 
2. They have high affinity for a variety of toxic metals including cadmium , copper , 
lead , zinc, and lanthanum. This property makes them a potential flushing agent in 
sites where bioremediation may be too slow or infeasible (32). 
3. They are effective against zoosporic plant pathogens, such as Pythuim 
aphonidermatum, Phytophthara capsici , and Plasmopara lactucae-radicis . In their 
pure forms RLs render the zoospores nonmotile and bring about their lysis in Jess 
than a minute at a concentration of 5-30 µg/ml (32) . Hence , they show potential for 
biological control , too . 
4. Due to their low toxicity ready biodegradability and excellent surface--active 
properties they could be of great value in the cosmetic industry ( 42). 
The antibacterial activity of RLs has not been fully explored nor exploited for 
commercial value. These compounds are active against both Gram-positive as well 
Gram-negative bacteria (1, 7, 20). The target for the action of rhamnolipids is the cell 
envelope (1), presumably the physicochemical properties of the compound are 
responsible for the permeabilization effect on the cell surface . 
Use of high density oligonucleotide microarrays 
to determine cellular response to inhibitors 
The entire genome of several bacteria are fully sequenced , annotated , and 
available in the public domain that can be used to assess the global impact of bacterial 
inhibitors on gene expression. This along with the latest developments in high density 
oligonucleotide microarrays represents a very powerful resource to understand the 
11 
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differential gene expression patterns in bacteria when subjected to different antimicrobial 
compound treatments (22, 41, 44 ). By analyzing differential gene expression patterns of 
bacteria when subjected to sub-MIC doses of antimicrobials , we have an opportunity to 
uncover adaptive mechanisms employed by bacteria at the genomic level to overcome the 
antimicrobial stress and also look at various secondary cellular responses. Stress 
responses thus induced can be used to detect and characterize the mode of action of these 
antimicrobials (9). In contrast to using single copy gene fusions (9) use of high density 
oligonucleotide anays are better tools to understand the stress responses and when 
combined to various pathway mapping tools like KEGG (26, 37) or Metac yc (27) , they 
confer an opportunity to uncover the precise metabolic shifts leading to the expression of 
a particular phenotype . 
In context to the antimicrobials under investigation here , evidence is mounting 
that for poreforming peptides, membrane permealization may not be the only mechanism 
by which they inhibit bacteria (10). They may flocculate intracellular contents , alter 
cytoplasmic membrane septum formation , inhibit cell wall synthesis, bind nucleic acids , 
inhibit protein synthesis or inhibit enzymatic activity (10). Also , it has been observed that 
the antimicrobial activity may or may not correlate with the pore forming activity of the 
peptide because evidence is available that bacteria can repair their cytoplasmic membrane 
even when treated with lethal concentrations of the antimicrobial ( 45) giving conclusive 
evidence that alternate mechanisms of cell death may be involved. Hence, in the light of 
recent discoveries it becomes necessary to investigate the alternate mechanisms of the 
bactericidal effects of these compounds . Use of whole genome expression studies 
currently seems to be the best alternative to achieve that. 
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In light of the need for new antibiotics and the broad indu stria l applications of SPs 
and RLs, we have selected them for further study. We will use these compounds to 
determine their potential to inhibit foodborne illness organisms as well as other pathogens 
important to the agricultural sector. 
Hypothesis 
Syringopeptin 25A (SP 25A) and rhamnolipids (RLs) inhibit many species of 
bacteria and their mode of inhibitions are distinct from each other. 
The above hypothesis would be verified by realizing the following objectives. 
Objectives 
1. Screen candidate compounds for microbial inhibition and determine the minimum 
inhibitory concentration for these compounds against selected bacteria 
2. Based on results from the first objective, one organism will be used to determine 
the cellular response to sub-MIC levels of SP 25A and RLs using gene expression 
arrays. 
Completion of these objectives will demonstrate the utility of a two new classes of 
natural antibiotics to inhibit bacteria found in food and the environment. Specific 
commercial applications of these compounds may be possib le , but demonstration of those 
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applications is beyond the scope of this initial project. Use of gene expression arrays will 
offer insight into the mechanism of action and potential targets that are being inhibited by 
the compounds in the cell. Most importantl y, this study will determine the differences in 
the cellular response between two different classes of antibacterial compounds that are 
produced by pseudomonads to inhibit other bacteria. 
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Table 2.1 . Antimicrobial/antifungal secondary metabolites from pseudomonads. 
Toxin Pseudomonas species Chemical Class Reference 
Pyo Compounds P. aeruginosa Quinoline derivatives 8, 10 
Pseudomonic P. jluorescens Organic acid 8 
acid 
Pyrrolnitrin P. cepacia, Pyrrol derivatives 8, 10 
P. aureofaciens 
Pyoluteorin P. aeruginosa Pyrrol derivatives 10 
Azomycin P. jluorescens Pyrrol derivatives 10 
Rhamnolipids P aeruginosa Glycolipids 8, 10, 11 
Tabtoxin P . .syringae Monocyclic ~-lactam 8, 9 
Phaseolotoxin P . .syringae Sulfodiaminophosphinyl 8, 9, 10 
peptide 
Sperabillins P. jluorescens Substituted peptides 10 
2-n-hexyl-5-n- Pseudomonas spp . Substituted resorcinols 8, 10 
pentyl resorcinol 
& 5-n-heptyl 
resorcinol 
2,4 diacetyl P. jluorescens Substituted Phenols 8, 10 
phloroglucinol 
Obafluorin P. jluorescens ~-Jactones 10 
Tropolone Pseudomonas spp . Tropolone 10 
7-hydroxy P. cepacia Tropolone derivative 10 
tropolone 
Thiotropocin P. seudomonas spp . Tropolone derivative 10 
Phosphonomycin P. syringae Unknown 10 
Syringomycin P. syringae , Lipodepsinonapeptide 9, 10 
P. fuscovaginae 
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Pseudomycin P. syringae , Lipodepsinonapeptide 9, 10 
P. fuscovaginae 
Syringotoxin P. syringae , Lipodepsinonapeptide 9, 10 
P. fuscovaginae 
Syringostatin P syringae , Lipodepsinonapeptide 9, 10 
P. fitscovaginae 
Syringopeptin P syringae Lipodepsipeptide 9,10 
Tolaasin P tolaasii Lipodepsipeptide 9 
Viscosin P jluorescens Lipodepsipeptide 9 
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Table 2.2. Reported MIC values for SP 22A and SP 25A against selected organisms. 
MIC (~M2 
Organism Reference 
SP22A SP 25A 
Bacillus megaterium 1.56 3.12 (29) 
Bacillus globigii spores 2.08 2.08 Weimer, unpublished data 
Rhodococcus fascians 6.25 12.50 (29) 
Micrococcus luteus 12.50 37.50 (29) 
Listeria innocua 6.25 4.17 Weimer, unpublished data 
Salmonella enteridis 6.25 8.33 Weimer, unpublished data 
Mycobacterium smegmatis 1.63 NA (11) 
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Table 2.3. MIC values of rhamnolipids against selected organisms . 
Organism MIC RL Mixture References 
(µg /ml) 
Bacillus cereus var mycoides A TCC 11778 64 RL47T2 (7, 20) 
4 RLLB1 
Enterobacter aerogenes CECT 689 4 RLLB1 ( 1, 7) 
>256 M7 
Staphylococcus aureus ATCC 6538 8 RLLB1 (1, 7) 
128 M7 
Alternaria alternata 4 RLLB1 (7) 
Proteus mirabilis CECT 170 8 RLLBI (7) 
Alcaligenes faecalis 32 M7 (1) 
Serratia marcescens 16 M7 ( 1, 20) 
8 RL47T2 
Klebsiella pn eumoniae CECT 17832 0.5 RL47T2 (20) 
Clostridium perfringens 256 M7 (1, 20) 
128 RL47T2 
Escherichia coli 32 M7 (1 , 20) 
64 RL47T2 
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SP22 
CH3(CH2)6~CH(OH)CH2CCrOhb-Pro-Val-Val-Ala-Ala-Val-Val-Ohb-Ala-Val-Ala-Ala-Dhb--aThr-Ser-Ala ... Dhb I I 
Tyr-Oab-Dab-Ala 
SP25 
CH3(CH2)uCH(OH)CH2CO-Dhb-Pro-Val-Ala-Ala-Val-Lcu-Ala-Ala-Ohb-Val-Ohb-Ala-Val-Ala-Ala-Dhb-aThr-Ser-Ala-Val I I 
Tyr-Oab-Oab-Ala 
Fig . 2.1. Structures of two syringopeptins with an amino acid backbone of 22 and 25 
residues (6) . The fatty acids can either be 3-hydroxydecanoic or 3-hydroxydodecanoic 
acid . Abbreviations for non-standard amino acids are: Dhb is 2, 3-dehydroaminobutyric 
acid ; aThr is allothreonine. 
< 
' 
Fig . 2.2 Three-dimensional structure of SP 25A obtained by distance geometry 
calculations from NMR analysis of the syringopeptin in D20 at pH 3.6 (31). 
25 
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Fig. 2.3 . Generalized structure of a rhamnolipid. The carbon chain length may be n = 4, 6, 
8 of C8, C 10, Ct2- In dirharnnolipids, R1 is Hor 3-hydroxydecanoate and R2 is L 
rharnnosyl (1 ). 
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CHAPTER 3 
ANTIMICROBIAL SPECTRUM OF SP 25A AND RL'S AGAINST BACTERIA' 
Abstract 
Secondary metabolites from microorganisms are common sources of antibiotics. 
However, recent increases in bacterial infections, the decreasing availability of potent 
antibio tics and the increasing bacterial resistance to available antibiotics requires the 
search for new antibacterial compounds to be broadened. In this study we investigated the 
antimicrobial properties of two secondary metabolites from fluorescent pseudomonads -
syringopeptin 25A (SP 25A), a lipodepsipeptide produced by Pseudomonas syringae pv . 
syringae , and a rhamnolipid mixture, which contained two primary types of glycolipids 
produced by Pseudomonas aeruginosa. Human pathogens, food spoilage organisms, and 
fermentative bacteria from both Gram-positive and Gram-negative classes were tested to 
determine the inhibitory potential of these compounds. The rate of antimicrobial action 
was determined by monitoring the rate of uptake of propidium iodide during exposure to 
the compounds. Both compounds compromised the membrane of all the Gram-positive 
bacteria with the rhamnolipids acting significantly faster (3-433 times depending upon 
the organism tested) (p<0.05) than SP 25A. Inhibition was also confirmed by the 
microbroth dilution method to determine the minimum inhibitory concentration (MIC) . 
Both compounds inhibited all the Gram-positive organisms tested , as well as 
1 Coauthore d by Prerak T. Desai , Patricia J. Champine , and Bart C. Weimer. 
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Flavobacterium devorans with MICs ranging from 3 µg/ml to 32 µg/ml. Both 
compounds inhibited Mycobacterium smegmatis, Bacillus subtilis spores, and 
Clostridium sporogenes spores with an MIC of 4 µg/ml. Interestingly, these compounds 
acted synergistically to inhibit Listeria monocytogenes, thereby lowering the MIC for L. 
monocytogenes. No toxicity was observed during exposure of these compounds to mouse 
enteroendocrine, human embryonic kidney , and human lung fibroblasts. Taken together 
these data support the conclusion that both of these compounds have potential for use as 
antibacterial compounds which needs to be confirmed with in vivo studies. 
Introduction 
The ability to contro l infections due to microorganisms has been one of the single 
most profound developments in the history of health science. The initial success of 
antibiotics is now maned by the emergence ofresistant organisms (4) . Antibiotic 
resistance is a complex problem exacerbated owing to the versatility of the microbes, 
overuse of antibiotics, and the lack of patients completing the prescribed dosage ( 4). 
Among many issues of antibiotic resistance, one of the most troubling issue is the 
establishment of vancomycin resistant organisms (36). The solution to this complex 
problem remains to be identified, but discovery of new compounds is essential in solving 
this issue. 
One source of new antibiotics is the secondary metabolites of bacteria with 
different modes of action. The antimicrobial potential of secondary metabolites of 
fluorescent pseudomonads have been studied extensively (6, 11, 27). Among the most 
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well characterized compounds are those produced by Pseudomonas syringae and 
Pseudomonas aeruginosa . The ability of these organisms to inhibit competing 
microorganisms via a myriad of mechanisms has inspired the search for new compounds 
from these and other pseudomonads (6, 11, 27). Many pathovars of P. syringae produce 
non-specific toxins ( e.g. syringomycin, syringopeptin , coronatine , phaseolotoxin , 
syringotoxin, and tabtoxin) that increase the virulence of the organism to the host plant 
(6) . Some of these toxins have antimicrobial and antifungal properties (6) which fuels 
their use as biocontrol agents (22) . The most promising antibacterial activity is shown by 
syringopeptins (SP) (6, 10, 26, 42) . In nature , SPs cause electrolyte leakage by forming 
pores in the plasma membrane of plant cells, thereby promoting transmembrane ion flux 
that leads to plant necrosi s (20). SPs also have biosurfactant properties with a low critical 
micelle concentration (0.4-0 .9 mM) (12) that may aid in the spread of the organisms on 
the plant surface (6, 19). Additionally SPs, along with syringomycin induce stomata! 
closure in plants , thereby preventing entry of other pathogens , which effectively reduces 
competition by other organisms on the plant surface (14) . 
SPs are cyclic lipodepsipeptide s and are produced by many strains of P . .5yringae 
pv. syringae (2, 16, 38, 42) . Current ly, five different SPs have been identified. They vary 
in the fatty acid chain length and number and composition of amino acids in the peptide 
moiety (2, 5, 6, 16, 21) . SPs contain either 22 or 25 amino acids with the N-terminal 
being acylated with either 3-hydroxydecanoic or 3-hydroxydodecanoic acid to 2, 3-
dehydro-2-aminobutyric acid (5, 6, 21). An eight-member lacton e ring is formed due to 
the ester bond between allothreonine and C-terminal tyrosine (5, 6, 21 ). A high 
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percentage of hydrophobic amino acids are found in SPs with the peptide being 
composed ofD-amino acids primarily (5, 6, 21) ; however, the peptide sequence of the SP 
varies from strain to strain (5, 6, 21) . 
The mechanism of bacterial inhibition by SPs is unknown , however , initial studies 
indicate that SPs form pores in the cell membrane (3, 19, 20, 28 , 40). It is hypothesized 
that SP molecules adsorb onto the cell membrane via the hydrophobic acyl chain inserted 
between the phospholipids in the membrane . Once the adsorbed monomers form 
aggregates of sufficient concentration , a pore is formed (12, 19). However , this mode of 
action remains to be proven , as does the minimum number of SP molecules required for 
pore form ation . 
P. aeruginosa is the epitome of opportunistic pathogens in humans, but the wide 
interest in this organism not only stems from this but also from its wide catabolic 
potential and the array of compounds with antibiotic activity that it produces (11 ). Cell 
free culture supernatants from P aeruginosa were extensively used in therapy of 
diphtheria, influenza and meningitis in the first quarter of the previous century, and since 
it exhibited enzymatic properties it was called pyocyanase (27) . Subsequently , nearly 50 
antimicrobial substances have been characterized from fluorescent pseudomonads ( 11 ). 
This study focused on the antimicrobial properties of rhamnolipids (RL), which 
are glycolipids produced by some strains of P. aeruginosa (7, 11, 29, 3 5). RLs are 
usually a mixture of various homologues , depending upon the strain and carbon source 
provided during growth (30). Eleven different RL homologues have been identified in 
cultures of P. aeruginosa (17) and consist of one or two moieties of rhamnose cova lently 
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linked to a 3-~ hydroxy acid, where the chain length of the acid is 8, 10, or 12 carbon 
atoms. In some cases they may also have 3-hydroxy decanoate linked to the former fatty 
acid via an ester bond. The physiological role of a specific RL is not well understood , but 
they are thought to aid in emulsifying hydrophobic substrates for cellular metabolism (24, 
34); aid the cells in swarming motility under nutrient limitations (24); cripple the 
competing organisms for nutrients by the virtue of the surfactant activity (1, 7, 17); and 
may act as a virulence factor (31 ). In vivo RLs prevent macrophage phagocytosis of the 
organism by bringing about structural changes in the macrophages so they cannot 
associate with the bacteria (31 ). The target for the action of RLs against other bacteria is 
the cell membrane (1 ), presumably the surfactant properties of the compound are 
responsible for the permeabilization effect on the cell surface. In this study we 
hypothesized that SPs and RLs inhibit a wide spectrum of bacteria without causing 
toxicity to mammalian cell lines. If true , these compounds may represent new options for 
anti bacterial therapy. 
Materials and Methods 
Purification of antimicrobials. Syringopeptin 25A (SP 25A) was produced and 
purified from Pseudomonas syringae pv . syringae Ml as described by Bidwai et al. (9). 
In brief, the culture was grown to stationary phase for 10 d standing culture at room 
temperature (-25°C). After collection of the supernatant SP 25A was extracted with 
acidified acetone, concentrated with a rotary evaporator, purified to homogeneity by 
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reverse phase HPLC, and lyophilized for storage at 4 ·c until further use . Purity and the 
molecular weight of the compound were verified by MALDI-TOF analysis at the Center 
for Integrated BioSystems (Logan, UT). 
Commercial RL samples were obtained as 25 .1 % aqueous solution (product JBR-
425 ; Lot#021004) from Jeneil Biotech , Inc. (Saukville , WI). The purity and molecular 
weight of the RLs were determined using MALDI-TOF at the Center for Integrated 
BioSystems . The relative concentrations via molar ratios between the two different 
rhamnolipid moieties (Decanoic acid , 3-[(6-deoxy-L-mannopyranosyl) oxy]-1-
(carboxymethy l) octyl ester , and Decanoic acid , 3-[(6-deoxy-2-0 (6-deoxy-L-
mannopyranosyl)-L-mannopyranosyl] oxy ]-1-( carboxymethyl)octyl ester) in the 
commercial rhamnolipid mixture were determined by 13C NMR as described by Sim et al. 
(39) . 
Determination of rate of antimicrobial action and the MICs against bacteria The 
antimicrobial action for each compound was initially determined by the rate of uptake of 
propidium iodide (PI) (Fluropure grade , Molecular Probes, Inc.; Eugene , OR) as 
previously described (18). In brief, all cultures were grown overnight in their respective 
optimal growth medium and temperature from freezer vials (Table 3 .1 ). Each culture 
was sub-cultured twice, harvested in mid log phase , washed with saline and adjusted to 
an OD600 of 0.25 in saline. PI, with an excitation wavelength of 535 and an emission 
wavelength of 617, was added to the culture suspension at a final concentration of 10 
µM. Each organism was treated with 50 µg/ml SP 25A and 60 µg/ml of the RL mixture 
in a final volume of 2.2 ml. The increase in fluorescence was measured with a Shimadzu 
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RF 1501 spectrophotoflurometer (Columbia , MD) at 15 s interval s for a maximum period 
of 120 min . Saline was added in place of SP 25A or RLs as a negative control . All 
inhibition experiments were done in two biological replicates. 
The rate of antimicrobial action was expressed as the inhibition rate (IR) (Eq. 1 ). 
The curve fitting was done using OriginPro Ver 7.0 (Natick , MA). 
IR = ((Log RFU/ (Time)) - C) / Time (when d Log RFU/ dT > 0) 
Where RFU = relative fluorescent units ; and C = Y intercept 
(Eq. 1) 
The minimum inhibitory concentration (MIC) for the organisms were determined 
by microbroth dilution method as prescribed by the National Committee for Clinical 
Laboratory Standards (NCCLS) (44). The microorganisms were prepared as described 
above and resuspended in their optimal growth media (Table 3 .1) to - 105 CFU/ml 
containing SP 25A at 2, 3, 4 , 5, 6, 7, 8, 16, 32 and 50 µg/ml in a total volume of 550 µI. 
RL concentrations of 2, 3, 4, 5, 6, 7, 8, 16, 32 and 60 µg/ml in a total volume of 550 µl 
were tested in a 48-well plate (Corning , NY) , unless otherwise noted. The plates were 
incubated in optimal growth conditions for the respective organism and monitored for an 
increase in OD6oo after 48 h by a Perkin-Elmer (HTS 7000) plate reader (Downers Grove , 
IL) . A positive control (inhibition of growth) using Polymyxin B (Sigma-Aldrich Cat# 
P0972) at 1000 µg /ml for all Gram-negative organisms, Penicillin G (Sigma-Aldrich 
Cat# P3032) at 1000 µg/ml for the Gram-positive organisms, Rifampicin (Sigma-Aldrich 
Cat# 3501) at 1000 µg/ml was used for M smegmatis, Enterococcusfaecalis and 
Staphylococcu s aureus . Negative controls (no inhibition of growth) were included using 
saline in the assay for each compound. The least concentration at which there was no 
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increase in OD over 48 h was reported as the MIC. Each MIC was determined in two 
biological replicates with triplicate tests per replication. The triplicates were averaged for 
each replicate reported. 
Synergistic activity between SP 25A and RLs was measured by exposing L. 
monocytogenes to RLs at a concentration of 0, 0.5, 1, 1.5, 3, and 6 µg/ml alone and in 
combination with 3 µg/ml SP 25A and monitoring PI uptake as previously described . The 
experiment was done in two biological replicates . 
Determination of cytotoxicity in cell culture. Toxicity of the two compounds to 
mammalian cells was assayed in cell culture using mouse enteroendocrine cells (STC-1) 
(37), human embryonic kidney cells (HEK 293; ATCC CRL-1573), and human lung 
fibroblasts (LL47 ; ATCC CCL-135) . Each cell line was subjected to SP 25A and RLs at 
the observed MIC (e.g. 4 µg/ml and 8 µg/ml) . The human embryonic kidney cells and 
hurnan lung fibroblasts were grown as per the ATCC recommendation, while the mouse 
enteroendocrine cells were grown as described by Vincent et al. (37). Media and sera 
were purchased from HyClone Laboratories (Logan, UT). All cells were grown in 10% 
fetal bovine serum (FBS). 
The number of total cells and dead cells were counted after 6, 24, and 48 h using 
a Nucleocounter Automated cell counting system (New Brunswick ; Edison , NJ). In brief , 
cells (STC - 200,000 cells/well , HEK 293 - 200,000 cells/well and LL47 - 100,000 
cells/well) were incubated with the appropriate medium for 24 h prior to addition of fresh 
media containing the antimicrobial compounds . After addition of the antimicrobial 
compound the cell cultures were incubated at 37°C with 5% CO2 for 6, 24, and 48 h. 
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Cells were harvested by trypsinization using 0.25% trypsin-EDT A for 2 min . The trypsin 
was neutralized by addition of 200 µl of serum containing fresh medium . The cells were 
harvested and transferred to 1.5 ml tubes , centrifuged (3-5 min at < l 00 x g), and 
resuspended in 200 µl of fresh medium. Subsequently , for total cell count 100 µl of the 
cell suspension was added to the Ly sis buffer (Reagent Al 00 in the starting kit (Cat No. 
Ml293-0020, New Brunswick Scientific) for 30 s, which was stabilized using 100 µl of 
Reagent B. A positive control of completely lysed cells by lysing all the cells with triton 
was used along with a negative control using sterile PBS (pH 7.4) . For dead cell counts 
100 µl of cell lysate was counted without use of lysis buffer or stabili zing buffer. All cell 
counts were obtained using the Nucleocounter automated cell counting system . Data were 
reported as the percent of cell death. The toxicity testing was done in two biological 
replicates with triplicate wells per replication . The triplicates wells per replication were 
averaged before reporting the replicate reading. 
Results and Discsussion 
Compound purity. After purification SP 25A was subjected to MALDI-TOF and 
HPLC analysis to confirm the purity of the fractionated compound. HPLC analysis 
revea led a single peak , as did MALDI TOF (Appendix A, Fig A l ). This single major 
peak had a molecular weight of 2,400.37 Da, which was in agreement with the reported 
size (33). 
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The commercial RL preparation was subjected to MALDI-TOF analysis and 13C 
NMR to determine the relative concentration and isoform content, respectively. MS 
analysis revealed Rhamnose-C 10-C 10 (MW = 503 .31) and Rhamnose-Rhamnose-C 10-
C10 (MW= 649.33) (Appendix A, Fig A2). These observations are in agreement with the 
product data sheet. NMR analysis demonstrated that the isoforms were present in an 
equimolar ratio. 
Bacterial inhibition by SP and RLs. It is thought that these compounds target the 
cell membrane, inducing lysis (6, 12, 25) . This study used PI, a membrane impermeant 
nucleic acid stain , as a probe to monitor cell membrane integrity during cellular exposure 
to both compound types (18). PI accumulation directly correlated to increasing exposure 
time for each compound , indicating that the compounds compromised the cell membrane. 
As such , the rate of PI accumulation (Eq . 1) was used to compare the inhibitory rate for 
each organism tested (Fig. 3 .1 ). 
SP 25A was not inhibitory to any of Gram-negative organisms tested except F. 
devorans , while it inhibited all Gram-positiv e organisms tested . Also , SP 25A did not 
inhibit the growth of any yeast tested (Breltonomyc es bruxellensis, Candida vini, Pichia 
ferment ans, Saccharomyces luduigi, Metschinikowia pulcherrima , Kloeckera apiculata) 
(data not shown). The greatest rate of inhibition was found for Brevibacterium linens, 
while E. faecalis had the slowest rate of inhibition (Fig. 3 .1 ). 
As observed with SP, RLs inhibited only Gram-pos itive bacteria (except F. 
devorans) , with activity being the fastest against B. subtilis (Fig. 3.1) and slowest against 
both the two Listeria species tested . The rate of action was distributed differently relative 
to SP 25A , but the same Gram-reacting organisms had the same inhibition for each 
compound . 
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There was a significant difference (p<0.01) in the rate of PI accumulation (IR) 
between SP 25A and RLs. Depending upon the species RLs were 3 to 433 times faster in 
the compromising the cell membrane as compared to SP 25A, the difference being 
highest for enterococci and lowest being for the Listeria species 
While the rate of action indicates the speed to compromise the membrane, an 
indication of the MIC is required to demonstrate inhibition of growth. Therefore , the MIC 
for each compound was determined (Table 3.2) . Measuring inhibition with MICs 
confirmed the observations using PI. 
The SP 25A MIC ranged from 3 to 16~tg/ml, while the MICs for RL ranged from 
4 to 32µg /ml for the organisms tested. Interestingly , a difference in the SP 25A and RL 
MIC with E. fa ecal is and S. aureus was observed (Table 3.2). While the MIC for RLs for 
both these organisms was >60 µg/ml , SP 25A completely inhibited both the organisms at 
8 µg/ml. For all the other organisms SP 25A had a similar or lower MIC as compared to 
RLs . Interestingly , both compounds inhibited spore germination from Bacillus and 
Clostridium at 4µg /ml. This work is the first report of anti-spore activity by these 
compounds. Both the organisms inhibited growth of M smegmatis at 4µg /ml. 
Lavermicocca et al. (26) measured the antibacterial activity of SP 25A using six 
organisms. No inhibition was observed for the three Gram-negative organisms, even at 
120 µg/ml. However , all three Gram-positive bacteria were inhibited (Micrococcus 
luteus, Bacillus megaterium , and Rhodococcus facians). While the overall observations 
are in agreement between this study and Lavermicocca et al. (26), the exact 
concentrations are not comparable, unfortunately, due to differences in methodology. 
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Antimycobacterial activity was found by Buber et al. (10), but due to the method 
of isolation they were unable to conclusively assign this activity to SP 25A. In this study 
we conclusively found that SP 25A inhibited M smegmatis, a surrogate organism for 
Mycobacterium tuberculosis, at 4 µg/ml. 
The literature contains conflicting reports on the spectrum of activity for RLs. 
This may be attributed to the fact that different groups have used RL mixtures with 
different compositions of RL homologues . For example , Abalos et al. (1) , Benincasa et 
al. (7), and Haba et al. (17) reported that RL mixtures are active against both Gram-
positive and Gram-negative bacteria . In this study , we found RLs that were active against 
Gram-positive bacteria and only one Gram-negative bacterium (F. devorans) at <60 
µg/ml. Kim et al. (8) reported the ability of RLs to lyse zoospores from Phytophthora 
capsici within 1 min at a concentrations <50 µg/ml. Conversely , we observed that RLs 
inhibited bacterial spore germination in B. subtilis and C. sporogenes at 4 µg/ml. 
Synergistic activity. Since both compounds demonstrated a similar range of 
activity and MICs , we determined the synergistic activity in an effort to reduce the MIC 
for each compound. This was done by exposing L. monocytogens to mixtures of SP 25A 
at 3 µg/ml with various RLs concentrations. The IR for the mixture of both the 
compounds was significantly different (p<0.05) than the IR of the compounds used alone 
across all concentrations tested , hence satisfying the classic definition of synergism. We 
achieved a higher rate of antimicrobial action when both the compounds were used in 
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combination as compared to individual use. Using the compounds together we were able 
to achieve the same level of inhibition with up to 6-fold less RLs. The increase in 
synergism followed a sigmoidal curve (Fig 3.2) . 
This is the first study to define the synergistic activity of SP 25A and RLs . Woo et 
al. ( 43) reported synergistic activity of SPs with fungal cell wall degrading enzymes to 
inhibit fungal pathogens . Also , there have been reports of synergism between cationic 
pore forming peptide s (23) , but there has been no report of synergism between a 
lipodepsipeptide and a glycolipid . The importance of this finding is best refined for use 
in specific applications , and is therefore beyond the scope of this work. 
Cellular toxicity . Three mammalian cell lines were used to assess cytotoxic 
effects for each compound at 4µg/ml and 8µg /ml. No significant (p>0.05) cytotoxicity 
was observed at 6, 24, and 48 h after treatment for each compound at either 
concentrations (Fig . 3.3). While a small amount of lysis was observed, it was not above 
background . Cells treated with triton (positive control) showed 100% lysis. These 
observations indicate that neither compound compromised the host membrane. Various 
groups (13, 15, 41) reported haemolytic activity of SP 25A. Menestrina et al. (15) 
reported a Cso value of 8.88 µg/ml of SP 25A for RBC hemolysis. In contrast , at similar 
concentrations, we did not observe membrane permeabilization of any of the three cell 
lines tested. A possible explanation of this observation is that RBC's lack an 
endomembrane, which is thought to play a central role in the rapid resealing response in 
event of plasma membrane disruption (32) . 
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Although structurally different both the compounds have a similar spectrum of 
activity for the strains tested . One aim of this study was to determine the use of these 
compounds against multiple drug resistant strains. This was done using E. faecalis and S. 
aureus that are gentamicin/vancomycin/teicoplanin resistant and MRSANISA , 
respectively. We observed that RLs had a higher IR than SP 25A, yet RLs were unable 
to inhibit growth at 60 µg/ml. This is similar to the concept described by Wu et al. ( 45) , 
who found that cationic peptides were not correlated with the ability to permeabilize the 
cell membrane and the antimicrobial activity. 
Several inferences can be made from this lack of correlation . The biochemical 
changes brought about by RLs were overcome by a stress response that repaired the 
compromised membrane , but they could not repair the changes brought about by SP 25A. 
This reveals that either the compounds have a differing mode of action on the cell 
membrane or SP 25A has multiple modes of action (i.e. it may act on multiple cellular 
targets) . Membrane repair in response to cationic peptides was reported by Wu et al. 
(45). They observed that some peptides did not depolarize the cell membrane at MIC 
concentrations , suggesting that at these MICs bacteria repaired their cell membrane and 
that a mechanism other than membrane disruption leads to cell death. In this study , we 
observed RLs to disrupt the membrane enough to up take Pl, yet the organisms retained 
the ability to replicate. 
This study demonstrated the ability of SP 25A and RLs to compromise the 
membrane of Gram-positive bacteria with MI Cs of S8 µg/mJ. The compounds acted 
synergistically to inhibit L. monocytogenes resulting in lower MICs for each compound 
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when used in combination . Considering the inhibition of multiple drug resistant 
enterococci and staphylococci , Mycobact erium, Bacillus spores , and the lack of toxicity 
towards mammalian cells makes SP 25A a very promising therapeutic agent , which needs 
to be confirmed with in vivo studies . 
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Table 3 .1. List of bacteria used for antimicrobial scree nin g and their growt h conditions . 
Organism Strain 
Temperature Oxygen Medium (°C) Demand 
13137 30 Aerobic 
Nutrient 
Aeromo nas caviae 
agar 
10987 30 Aerobic 
Nutrient 
Bacillus cereus 
agar 
Bacillus subtilis 23857 26 Aerobic 
Nutrient 
agar 
Bacillus megaterium 14581 30 Aerobic NB 
Brevibacterium linens BLl 37 Aerobic TSB MGE 
Citrobacter fruendii 11811 37 Aerobic Nutrient 
agar 
Reinforced 
Clostridium sporogenes 10000 37 Anaerobic clostridial 
medium 
Enterobacter aerogenes 13048 30 Aerobic Nutrient 
agar 
Enterococcus fa ecal is 700802 37 Aerobic BHI 
Erwinia herbicola 33243 37 Aerobic Nutrient 
agar 
Eschereschia coli K12 37 Aerobic Nutrient 
agar 
Eschereschia coli H7:0l 57 35150 37 Aerobic Nutrient 
agar 
Flavobacterium devorans 10829 30 Aerobic Nutrient 
agar 
Klebsiella pneumoniae sub sp 700721 37 Aerobic NB pneumoniae 
Lactobacillus plantarum 8014 37 Microaerophilic MRS 
Lactobacillus acidophilus 4355 37 Microaerophilic MRS 
Lactococcus lactis subsp lactis IL1403 30 Microaerophilic Ellikers Broth 
Listeria innocua 33090 37 Aerobic BHI 
Listeria monocytogenes 43251 37 Aerobic BHI 
Micrococcus luteus 21102 30 Aerobic BHI 
Mycobacterium smegmatis 14468 37 Aerobic Luria Broth 
Saimonella typhimurium 13076 37 Aerobic Nutrient 
48 
agar 
Salmone lla enteridis 700931 37 Aerobic TSB 
Staphylococcus aureus subsp 700699 37 Aerobic BHI 
aures 
Streptococcus mutans 89/1591 37 Aerobic BHI 
Streptococcus suis 700610 37 Aerobic BHI 
Streptococcus agalacticae 12403 37 Aerobic BHI 
Bacillus subtilis (spores) 6633 26 Aerobic TSB 
Reinforced 
Clostridium sporogenes(spores) 11437 37 Anaerobic clostridial 
medium 
49 
Table 3.2. MICs (Two biological replicates done in duplicate) and mean IR's (2 
biological replicates) of SP 25A and Rhamnolipid mixture against screened organisms. 
(ND represents Not Determined). 
IR IR SP 
Genus Rhamnolipids MIC(µg /ml) 25A MIC(µg /ml) 
(60µg /ml) (50µg /ml) 
Bacillus megaterium 1.043 4 0.005 ,.., _) 
Listeria innocua 0.014 5 0.005 ,, _) 
Listeria monocytogenes 0.032 6 0.005 ,, _) 
Bacillus cereus 0.834 4 0.004 4 
Bacillus subtilis 1.807 4 0.006 4 
Clostridium sporogenes 0.698 4 0.008 4 
Flavobacterium devorans 0.518 16 0.002 4 
Lactococcus lactis subsp. Lactis 1.219 4 0.008 4 
Micrococcus luteus 0.183 8 0.006 4 
Mycobacterium smegmatis ND 4 ND 4 
Streptococcus mutans 0.164 4 0.003 4 
Streptococcus suis 1.018 4 0.006 4 
Bacillus subtilis (spores) ND 4 ND 4 
Clostridium sporogenes(spores) ND 4 ND 4 
Enterococcus faecalis 0.482 >60 0.001 8 
Lactobacillus acidophilus 0.196 16 0.003 8 
Staphy lococcus aureus subsp. aureus 0.894 >60 0.003 8 
Streptococcus agalacticae 1.073 4 0.004 8 
Lactobacillus plan/arum 0.287 32 0.003 16 
Aeromonas caviae 0.000 >60 0.000 >50 
Citrobacter fruendii 0.000 >60 0.000 >50 
Enterobacter aerogenes 0.000 >60 0.000 >50 
Erwinia herbicola 0.000 >60 0.000 >50 
Eschereschia coli Kl 2 0.000 >60 0.000 >50 
Klebsiella pneumoniae subsp. 
Pneumoniae 0.000 >60 0.000 >50 
Salmonella typhimurium 0.000 >60 0.000 >50 
Salmonella enteridis 0.000 >60 0.000 >50 
Brevibacterium linens 0.512 ND 0.009 ND 
Eschereschia coli H7: 015 7 0.000 ND 0.000 ND 
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CHAPTER4 
GENE EXPRESSION PROFILE OF LISTERIA MONOCYTOGENES EGDE IN 
RESPONSE TO SUB-MIC DOSES OF SYRINGOPEPTIN 25A AND 
RHAMNOLIPIDS 
Abstract 
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Two antimicrobial compounds that target the cell membrane , syringopeptin 25A 
and an equimolar mixture of two rhamnolipids , were used to determine the cellular 
response during sub-MIC treatment with Listeria monocytogenes EGDe. Cell growth, 
membrane permeabilization and the gene expression profile was determined immediately 
prior to treating the cells with either antimicrobial , after 30 min of exposure , and after 
120 min of exposure . Cell membrane permeabilization was highest after treating the cells 
with rhamnolipids , which also resulted in a 4 7 % reduction in growth. However, growth 
inhibition was 100% after treatment with SP 25A, despite having only - 2% increase in 
dye uptake . Treatment of L. monocytogenes with SP 25A significantly changed the 
expression of 139 genes , while treatment with rhamnolipids resulted in significantly 
different expression of 3 9 genes. SP 25A repressed 97% of the differentially regulated 
genes, while RLs induced 70% of the differentially regulated genes after 120 min of 
treatment. The effective reduction in cell density after treatment with SP 25A was 
associated with the repression of key genes involved in cell division and genome 
replication; hence , inhibiting cell division. SP 25A also repressed key genes in central 
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metabolism , generation of precursor metabolites , transcription, and translation resulting 
in repression of RNA production , protein biosynthesis, cellular energy , and virulence. 
Rhamnolipids , conversely , affected only a few genes within any single functional 
category that were not associated with any single phenotypic observation . Hence , SP 25A 
caused repression in the cell's metabolism , which was independent of the observed pore 
forming activity. Taken together these data led us to conclude that both the compounds , 
even-though acting on the cell membrane , produced distinctly different gene expression 
profiles with SP 25A being more effective to inhibit cell growth in L. mono cytoge nes. 
Introduction 
The increase in multiple antibiotic resistant strains , which leads to more 
nosocomial infections and community-acquired infections , has fueled the search for new 
antibacterial compound s, including peptides. Antimicrobial peptides are pervasive 
components of prokaryotic and eukaryotic defense mechanisms against invading 
organisms (9). Though structurally diverse , the amphipathicity and cationic nature of 
these peptides allows them to interact and disrupt the bacterial cell membrane leading to 
cell death (3 5). Subsequent effects on intracellular molecules have also been observed , 
leaving some investigators to conclude that membrane disruption is only a portion of the 
antimicrobial activity (16, 36) . 
The mode of action to disrupt the membrane with peptide antibiotics is thought to 
follow the "barrel stave" model that form pores across the membrane or the "carpet" 
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model, where the molecules align orient parallel to the membrane and disrupt the lipid 
structure (28) . While it seems alluring to endow the antibacterial effect of these 
compounds solel y to thes e two models , these mechani sms alone do not account for the 
physiological effects that these peptide s produce in bacterial culture s (8). Wu et al. (35 ) 
and Friedrich et al. (16) observed that some cationic peptides failed to depolarize the 
bacterial membrane , yet effectively inhibited growth. At the MIC concentration these 
peptides did not disrupt the bacterial membrane , giving conclusive evidence that a 
general membran e disruption mechanism alone cannot account for antimicrobial 
properties of all peptide s (15 , 35). Furth er, Tomasin sig et al. (32) and Hon g et al. (17 ) 
found that cationic peptides resulted in changes in gene expression profiles in E. coli in 
addition to perrneabilizing the membrane. Taken together , these data provide evidence 
that it is unlikely that the diverse groups of peptides act via only membrane disruption 
alone . Once inside the cytoplasm these peptides may bind proteins , DNA , RNA , or other 
macromolecules to alter replication and metabolism (8) . 
Cyclic lipopeptides are potent antimicrobial and two compounds of this class 
polymyxin B (14) and daptomycin (26) are approved by the Food and Drug 
Administration for clinical use . Syringopeptin 25A (SP 25A), a cyclic lipodepsipeptide 
produced by Pseudomonas syringae pv. syringae is structurally similar to daptomycin. SP 
25A consists of 25 amino acid residues with the N-terminal being acylated with 3-
hydroxydecanoic acid. An eight -member lactone ring is formed via an ester bond 
between allothreonine and C-terminal tyrosine (3, 5, 19). Hydrophobic amino acids 
account for 68% in syringopeptins with the peptide being composed of primarily D-
amino acids (3, 5, 19). 
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In a previous study, rhamnolipids (RLs) showed a similar spectrum of activity to 
inhibit bacteria , as compared to SP 25A (13). RLs are surfactants with 11 homologues 
produced by some strains Pseudomonas aeruginosa and consist of one or two moieties of 
rhamnose covalently linked to a 3-~ hydroxy acid, where the chain length of the acid is 8, 
10, or 12 carbon atoms (6) . In some cases they may also have 3-hydroxy decanoate 
linked to the fatty acid moiety via an ester bond. RLs are usually a mixture of various 
homologues , depending upon the strain and carbon source provided during growth (23) . 
In a previous study Desai and Weimer (13) found no correlation between the bactericidal 
activity and membrane permeabilization of SPs and RLs. In a multi drug resistant strain of 
Staphylococcus aureus, RLs induced higher propidium iodide (PI) uptake , indicating an 
increase in membrane penneabilization , as compared to SP 25A, but RLs did not inhibit 
the cell growth. This confirms the observations of others for the disconnection of 
membrane disruption and growth inhibition (8, 13, 15, 16, 18, 33, 35). 
A number of groups have used transcription profiling during challenges with sub-
MIC doses of antimicrobial compounds to find that some antimicrobial peptides invoke 
cellular changes that are not lytic and not lethal (1, 10, 17, 32, 34 ). These experiments are 
leading to the discovery of the multiple targets for antimicrobial peptides beyond the 
membrane . Such observations imply that the peptides directly or indirectly interact with 
membrane proteins leading to regulatory components, which affects the susceptibility of 
the organism to the compound, which has been observed in Salmonella enterca and P. 
aeruginosa (32). In this study, we hypothesized that sub-MIC doses of SP 25A or RLs 
will evoke distinct gene expression responses that will provide genetic targets that are 
additional mechanisms of action to inhibit bacterial growth that are not membrane 
associated. 
Materials and Methods 
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Purification of antimicrobials . P. syringae pv. syringae Ml was obtained from the 
Utah State University culture collection. SP 25A was produced and purified as described 
by Bidwai et al. (7). In brief, the culture was grown to stationary phase for 10 d standing 
culture at room temperature (- 25°C). After collecting the supernatant , SP 25A was 
extracted with acidified acetone, concentrated with a rotary evaporator , purified to 
homogeneity by reverse phase HPLC , and lyophilized for storage at 4 °C for further use . 
The purity and molecular weight were verified by MALDI -TOF analysis at the Center for 
Integrated BioSystems (Utah State University , Logan, UT). 
Commercial RL samples were obtained as a 25 .1 % aqueous solution (product 
JBR-425; Lot#021004) from Jeneil Biotech, Inc. (Saukville , WI). The purity and 
molecular weight of the RLs were determined using MALDI-TOF at the Center for 
Integrated BioSystems. The relative concentrations via molar ratios between the two 
different rhamnolipid moieties (Decanoic acid , 3-[(6-deoxy-L-maimopyranosyl) oxy ]-1-
(carboxymethyl) octyl ester, and Decanoic acid, 3-[(6-deoxy-2-0 (6-deoxy-L-
mannopyranosy l )-L-mannopyranosy l] oxy ]-1-( carboxymethyl )octy 1 ester) in the 
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commercial rhamnolipid mixture were determined by 13C NMR as described by Sim et al. 
(29) . 
Bacterial strain, growth conditions and gene expression profiling. Listeria 
monocytogenes EGDe was thawed and subcultured twice at 37°C in brain heart infusion 
broth (BHI) (DIFCO , Franklin Lanes, NJ). An overnight culture was diluted 10 fold in 
sterile medium and grown for 4 h to an OD600 of 1. 7, which corresponded to ·- 109 cfu/ml. 
The cell preparation was exposed to either 3µg /ml SP 25A or 6 µg/ml RLs. Previously, 
Desai and Weimer (13) determined the MIC for L. monocytogenes with SP 25A to be 3 
µg/ml and 6 µg/ml with RLs . This study used these concentrations , but increased the cell 
population to - 109 cfu/ml, rather than 105 cfu/ml , the cell density used to determine the 
MIC. Thereby, making SP 25A and RLs sub-MIC at 3 µg/ml and 6 µg/ml , respectively . 
Total RNA was extracted from 1.8 ml culture immediately before treating the 
cells with SP 25A and RLs (To), after 30 min (T30), and at 120 min (T120) of exposure at 
37°C. Simultaneously, the cell density was measured at OD600. Membrane 
permeabilization was determined by measuring the PI uptake as described by Desai and 
Weimer (13). Total RNA extraction and reverse transcription (from 10 µg total RNA) 
was done as described by Yi et al. (36) to produce biotinylated cDNA, which was sheared 
with DNasel as described by the protocol ofNimbleGen Systems (Madison, WI). The 
custom, optimized NimbleScreen chip contained 12 wells, enabling the entire experiment 
to be done on a single chip. Each well contained five probes for each open reading frame 
in the entire genome. 
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Hybridization of the fluorescently-labeled (Cy3 -st reptavidin ; Amers ham 
Biosciences , Piscataway , NJ) cDNA (500 ng) was done using a custom NimbleScreen 
chip optimized for L. monocytogenes EGDe, as described by the NimbleGen Systems 
protocol. Hybridization was detected with a Genepix 4200A array scanner (Axon 
Instruments , Union City, CA) at the Center for Integrated BioSystems. Data extraction 
from the scanned images was completed at NimbleGen Systems . The raw expression data 
from the entire experiment were normalized together using R with the robust multichip 
average (RMA) method ( 18). Appendix C lists the R code used for RMA normalization . 
Annotations for Listeria monocytogens EGDe were obtained from the ERGO database 
(Integrated Genomics , Chicago, IL) . 
Statistical analysis and data visualization. RMA normalized data were analyzed 
using SAM Version 2.01 (33) with a one class time course experimental design using the 
xCluster R module (Center for Integrated BioSystems). Any gene with at least a log2 ratio 
of ±0.58, which is equivalent to a 1.5 fold change, and a Q<0.3 was considered 
significant (30). The entire biological experiment was replicated twice. 
Heat maps were drawn with log2 values of the RMA normalized data after 
calculating the average of the biological replicates using Hierarchicai Clustering Explorer 
version 3.0 (27). The log2 ratios were calculated by taking a difference in log2 intensity of 
a single time point with the preceding time point. 
Results 
Compound purity and growth inhibition. The commercial RL preparation was 
tested using MS and 13C NMR to determine the isoform content and relative 
concentration , respectively. 13C NMR analysis revealed Rhamnose-C 10-C 10 (MW= 
503.31) and Rhamnose-Rhamnose-ClO-ClO (MW= 649 .33) to be present in an 
equimolar ratio . These observations are in agreement with the product data sheet. 
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The compound purity was tested to ensure the compound identity before use in 
the study of growth inhibition . SP 25A isolated in this study was a single compound 
(Appendix A, Fig Al) , but the commercial RL preparation was a mixture of two isoforms 
(Appendix A, Fig A2). The pure SP 25A had a molecular weight of 2,400 .37 Da, which 
was in agreement with the reported molecular weight for SP 25A (24) . 
Both antibacterial treatments caused membrane permeabilization (Fig . 4.1 A) , but 
reduced cell growth (Fig. 4.18) of L. monocy togenes by different amounts . Addition of 
RLs resulted in more membrane permeabilization than did the addition of SP 25A. After 
30 min of incubation with RLs the permeabilization increased by 53% ; while 
permeabilization due to SP 25A increased 2.6% during the same time . Interestingly , the 
permeabilization declined after 120 min of treatment with RLs. 
The cell density was highest in the control , as expected , and lowest with addition 
of SP 25A. The control culture increased growth by 15 .3 % during 120 min , while the 
culture treated with RLs increased by 8%, but those treated with SP 25A did not increase. 
The membrane permeabilization and the cell density changes did not correlate (Fig. 4.1 ), 
suggesting that the mechanism of action for both compounds was not just membrane 
permeabilization. To determine the underlying mechanisms responsible for these 
differences, gene expression profiles were determined. 
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Gene expression profiling with RLs. The expression data were examined for genes 
that were constitutively expressed above the mean expression level , but none were found , 
indicating that gene expression changed over the exposure time. At T 30 RLs induced eight 
genes and repressed two genes. Treating the cells for 120 min with RLs significantly 
altered the expression of 39 genes. Regulation of 21 common genes was observed 
between SP 25A and RLs (Table 4.1 ). Despite regulating these common genes , the 
patterns of expression between the two classes of the antimicrobial compounds were 
different. At T120, 27 genes were induced and eight were repressed. 
Intermediary metabolism and oxidative phosphorylation. RLs induced three 
PEP/PTS components, a-mannosidase (LM00401), and five other genes involved in 
glycolysis and pentose phosphate pathway (Table 4.2). Conversely , all these genes were 
repressed when cells were treated with SP 25A during the same time period. The H+-
transporting ATP synthase C (atpE) was induced at T30, but subsequently repressed at 
T 120. Fig D 1 and D2 from Appendix D gives the heatmaps of genes affected in these 
functional category 
Protein biosynthesis and virulence factors. No genes related to transcription were 
differentially regulated after treatment with RLs. Only one gene related to protein 
biosynthesis, phenylalanyl-tRNA synthetase alpha chain (pheS (LM01221)) was induced 
at T30. An acetyltransferase (LM00624) involved in post translation modification was 
repressed at T3o, but induced at T120 (Table 4.2). Fig D3 and D4 from appendix D gives 
the heatmaps of genes affected in these functional category 
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Of the four virulence factors in the genome , only listeriolysin O (hly) was induced 
after 120 min of treatment. Expression of the remaining virulence factors was not 
change d by addition of RLs. 
Stress genes. Four stress -related genes -- single strand bindin g protein (ssb), non-
heme iron binding ferr itin (fri), and heat shock protein cspL, and peroxide operon 
regulator p erR (LM01683) -- were induced after 120 min . However , none of the genes in 
the perR regulon were induc ed. No other genes were significantly regulated durin g 
treatm ent with RLs. 
Gene express ion pro.filing with exposu re to SP 25A.Treat ing L mono cytogenes 
with SP 25A significantly altered the transcript profile of - 5% of the genes of the 
genome. Addition of SP 25A repressed 97% of the 139 differentially regulated genes 
(Table 4.3). The data set was also analyz ed for genes that were constitutively expressed 
above the mean level during the treatment in an effort to find genes that may be essential 
for survival of bacteri a under the antimicrobial stress . No genes were found that were 
constitutively expressed above the mean . Most functional categori es contained genes that 
were repressed . No categories contained genes that were only induced . However , a few 
categories (ABC transporters , carbohydrate metabolism , transcription regulators, 
secretion, virulence factors, and unknown genes) contained genes that were induced and 
repressed. 
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Cell division. Four genes involved in cell division and chromosome replication 
were repressed. Genes required for cell division initiation protein , Div IV A (LMO 1888), 
ATPase associated with chromosome architecture /replication (LM02759), DNA gyrase 
subunit B (gyrB) , and DNA gyrase subunit A (gyrA) were repressed with addition of SP 
25A. The transcription factor , lytR, which is correlated to the decrease in activity of 
autolytic enzymes (11), was also repressed (Table 4.4). 
Membrane prot eins. PEP/PTS transporters specific for ~-glucosides , fructose , and 
trehalose ; cx-mannosidase (a sugar hydro lase) ; and 22 other genes in carbohydrate 
metabolism were differentially expressed during the treatment time . From the entire set 
of genes in the intermediary metabolism category , only L-glutamine-fructose-6-
phosphate transaminase (LM00726) and 6-phospho-~-glucosidase (LM00739) were 
induced at T30. However , at T, 2o all of the 26 genes in sugar transport and intermediatery 
metabolism were repre ssed (Table 4.4). Eac h PEP/PTS components were repressed after 
120 min (Table 4.4). 
In addition to the sugar transporters and A TPases that were repressed, the large-
conductance mechonosensitive ion channel (LM02064) was induced at T30, but repressed 
at T120- This mechanoreceptor is involved in osmoregulation. Other studies using gene 
expression profiling did not observe an expression change in this ion channel , despite its 
importance in restoring the osmotic stability in a cell. This observation may be indicative 
of membrane perturbation early in the treatment time. 
Jntermediatery metabolism and respiration. The repressed genes in central 
intermediatery metabolism included genes involved in glycolysis - 6-phospho-beta-
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glucosidase (LM00739) , the pyruvate dehydrogenase operon (pdhA, pdhB , pdhC , pdhD), 
lactate dehydrogenase (ldh), pyruvate kinase (pykA), and phosphoglyceromutase 
(LM02205). Repression of genes in the pentose phosphate pathway were also observed -
ribose 5-phosphate isomerase (LM00736) , transaldolase (LM02743) , ribulose 5-
phosphate 3-epimerase (LM00735 , LM02659) , and fructose-1 ,6-bisphosphate aldolase 
(jbaA). The dihydroxyacetone kinase enzyme complex (LM02695 , LM02696 and 
LM02697) , which is responsible for phosphorylation of dihyroxyacetone and glycerol 
prior to entry into the glycolytic pathway , was also repressed. Four (out of six) genes 
involved in Fe-S cluster biosynthesis (sujD, lscU, sufB, cysteine desulfurase (LM02413)) 
were repressed. 
Repression of key genes for cellular respiration was observed. After 120 min , two 
genes ( out of eight) of the H+ transporting ATP synthase enzyme complex , which code 
for the alpha and c subunits (atpA and atpE) , were repressed. Three of the four subunits 
for quinol oxidase (LM00014, LM00015 , LM00016) were also repressed. 
Protein biosynthesis. At T30 two genes involved in protein biosynthe sis, 
(LM025 l 1 and rpsU) were induced. The gene LM025 l l codes for the ribosome 
associated factor Y, which is a global translation inhibitor , while rpsU codes for the S21 
protein in the 30s ribosomal complex. After 120 min of treatment with SP 25A, three of 
the four subunits of RNA polymerase (rpoA, rpoB, rpoC) were repressed . After 120 min 
1 1 ribosomal proteins ( out of 59) were repressed and two elongation factors ( out of total 
four) were repressed. Hence , after 120 min genes needed for transcription and translation 
were repressed . 
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Virulence factors. At T 30 two of the virulence genes hly (listeriolysin O precursor) 
and fibronectin binding protein (LM00727) were induced , while iap (an invasion 
associated protein) was repressed. At T 120, phospholipase C (plcA) was also repressed. 
Hence , after 120 min SP 25A led to the repression of four genes directly required for host 
invasion by L. monocytogenes. 
Stress response. At T30 five stress-related genes were repressed , while four genes 
were induced. Among the repressed gene s two chaperone protein s (groEL, grpE), tlu·ee 
oxidative stress genes (sod , msrA , trxB) , and one gene related to toxic ion resistance 
(LM01967). During the same period, the induced stress proteins were DNA binding 
protein (fri) , organic hydroperoxide resistance protein (LM02 l 99), arsenate reductase 
(LM02230) , and a universal stress protein (LMO 1580). After 120 min , an additional six 
stress related genes were repressed. These included hrcA (a negative regulator of class I 
heat shock genes) , a general stress protein (LMO 160 I) , a protein related to oxidative 
stress (msrB) , and three genes involved in DNA recombination and repair (i.e . single 
strand binding protein (ssb ), an endonuclease involved in recombination (LMO 1502), and 
exinuclease ABC subunit A (urvA)). Three ATP-dependent endopeptidases needed for 
protein turnover (clpE, clpB , clpX)(22) were also repressed . At T30 one transcription 
regulator of the marR family (LM02200) , which is a negative regulator of antibiotic 
resistance proteins in E. coli (2) was induced, while at T 120 another transcription of the 
same family (LM00266) was repressed. 
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Discussion 
This study explored the cellular response to treatment with two antibacter ial 
compounds that presumably target the cell membrane for inhibition (5, 12, 21). The cell 
permeabilization , cell density , and the transcription profile between these compounds 
were markedly different. RLs caused an increase of - 53% in membrane 
permeabilization , and inhibited growth by - 4 7%, a reasonable correlation between 
membrane permeabilization and growt h inhibition. Converse ly, SP 25A permeabilized 
the membran e by - 2%, but led to complete inhibiti on of cell growt h, demonstra ting the 
disconnection between membrane permeabilization and cell growth inhibition . Other 
studies with E. coli and S. aureus have made similar observations (16, 35). Friedrich et al. 
(16) observed that treatment of S. aureus with CP26, an a-helical peptide , led to only 
partial membran e depo larization, even with 90% inhibition of the population. Wu et al. 
(35) found similar results using CP26 and bactenecin in E. coli. Tomas insig et al. (32) 
found that a specific sequence of a praline-rich peptide interacted with the membrane 
leading to growth inhibition and that the same peptide fragment led to gene expression 
changes that were not related to membrane disruption. In contrast this study found RLs 
to be linked to membrane disruption to bacterial inhibition for lytic activities . 
Alternatively, use of SP 25A confirmed that additional mechanisms beyond membrane 
disruption for bacterial inhibition may be involved. 
With this observation , gene expression profiles were used to determine the genetic 
targets of these bacterial inhibitors . SP 25A significantly changed expression of 139 
genes , while RLs significantly changed expression of 39 genes. Both the compounds 
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affected twenty-one common genes , but the expression profile for all these genes ( except 
sujB) was significantly different. While SP 25A caused repression of all these genes after 
120 min of treatment , RLs caused an induction (Table 4.3) , lendin g support to the 
observation of growt h inhibition by SP 25A (Fig. 4 .1 ). Tomasinsig et al. (32) found that 
genes from the same functional categories to be repressed with the Bac7 ( 1-35) peptide 
fragment in E. coli. 
SP 25A repressed key genes involved in cell division . After 120 min four prot eins 
invo lved in cell divi sion were repres sed; two DNA gyrase subunits , one was an A TPase 
assoc iated with chromosome rep licat ion, and one was the cell division initiation protein, 
Div IV A, which is crucial for the initiation of cell division (15). Hence , repre ssion of this 
protein alone would inhibit cell division (15). RLs , in contrast , did not affect any of the 
proteins involved in cell division and had only a small reduction in cell density (Fig. 1 ). 
In addition , repression of ly tR was correlated to a decrease in autolytic enzyme activit y, 
which resulted in inhibition of cell divi sion in S. mutans (11 ). Use of SP 25A also led to 
repression of fytR in L. monocytog enes in this study. These observation s explain the 
inhibition of growth , rather than membrane disruption, with the addition of SP 25A. It 
also points to the regulatory link between lytR and Div IV A to completely inhibit cell 
growth (Fig. 4. lA , Table 4.4). 
SP 25A caus ed significant changes in intermediary metabolism, especially 
glycolysis and pathways needed for energy production (Table 4.4). Repression of central 
metabolism would lead to a lack of enzymes needed for generation of precursor 
metabolites and energy needed for growth. Repression of pyruvate dehydrogenase 
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complex (8- to 16-fold), pyruvate kinase (1.6 fold), and phosphoglyceromutase (1.5 fold) 
would virtually stop energy production from glycolysis. 
Glycolytic intermediates are also important for generation of acetyl CoA , 
pyruvate and phosphoglycerate, which are precursor metabolites for production fatty 
acids and amino acids . RLs induced expression of the E3 subw1it of pyruvate 
dehydrogenase , phosphoglyceromutase , and two more enzymes in the pentose phosphate 
pathway , indicating that glycolysis was induced and energy production improved . This 
may explain the reduction in membrane permeabilization after 120 min of exposure to 
RLs. In contrast , addition of SP 25A , five enzymes in the pentose phosphate pathway 
leading to generation of ribose-5-phosphate , which acts as a precursor metabolite in 
purine and pyrimidine metaboli sm, were repressed by 1.5-to 3- fold. The lack of 
induction of alternative pathways for formation of these metabolites left the cell with no 
method to produce energy or intermediates to use in cell division. The same repression of 
several key enzymes of the central intermediatery metabolism was also observed in E. 
coli when challenged with sub-MIC doses of Bac7(1-JS), including sugar transporters and 
glycolytic intermediates , which was associated with inhibition of cell growth (32). 
SP 25A led to a - 5-fold repression of four proteins needed for synthesis of Fe-S 
clusters . These are essential in diverse reactions , including electron transport , regulation 
of gene expression, and mediation ofredox as well as non-redox catalysis (4). SP 25A 
also caused down regulation of two subunits of the proton pump by 1.5-fold and quinol 
oxidase by 2-fold, causing disruption of the oxidative phosphory lation machinery . RLs in 
contrast led to a 3-fold induction of one subunit of proton pump (atp/<.,J at T30 and a 3.5-
fold repression at T 120. Hence, after 120 min SP 25A repressed the cells ability to 
generate precursor metabolites , as well as energy , while RLs did not have that effect at 
all. In E. coli, repression of iron metabolism was found only in transport (jecA), other 
genes were not affected (32). 
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Genes associated with transcription and translation were repressed between 1.5-
and 12-fold with the addition of SP 25A. It repressed three out of four RNA polymerase 
subunits by 1.5- to 2-fold , which completely disrupted transcription. Coupled to this 
decline , translation activity was also repressed. This effect was widespread with 
repression (1.5- to 4-fold) of 11 ribosomal genes after 120 min, and two elongation 
factors (2.5- to 12-fold). Contrary to this study, Tomasinsig et al. (32) observed an 
induction of ribosomal genes after exposure to a pro line rich antibacterial peptide. 
Regulation of stress-related genes was widespread with the addition of SP 25A 
(Table 4.4). Multiple systems were regulated during the exposure time , which included 
osmotic regulation , DNA repair , chaparonenes, and peroxide resistance. For example , 
the large conductance mechonosensitive channel (mscL) was induced at T30, but was 
repressed at T ,20. This gene is associated with hypo-osmotic shock (31) , likely caused by 
the interaction of SP 25A with the membrane. Induction of mscL demonstrates the cells 
effo1i to modulate the osmotic change with the addition of SP 25A. Repression of the 
membrane protein at T120 likely indicates that the cell is no longer under osmotic stress. 
This exp lanation seems likely considering the membrane permeabilization declined at 
T,20. No other group (17, 25, 32) has observed this phenomenon in response to an 
antimicrobial peptide, despite observing changes in membrane and transport proteins 
associated with sugar and ion flux. 
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Interestingly , in all cases, stress-associated genes were repressed after 120 min of 
exposure to SP 25A. This may indicate that the cell has adapted to the effects of SP 25A , 
but it may also represent the inability to produce new RNA and proteins with the 
repression of the transcription and translation apparatus observed in this study. Three 
Clp A TPase implicated in regulation of the stresses by virtue of their protein reactivation , 
remodeling activities , and their capacity to target misfolded proteins for degradation (22) 
were repressed by SP 25A. There are no reports in literature of stress related genes bein g 
repressed in response to exposure with antimicrobial peptides (1, 10, 17, 32, 34). 
Four virulence genes essential for intracellular survival of L. monocytogenes were 
repressed with treatment with SP 25A after 120 min of exposure. Fibronectin binding 
protein and hly were induced and iap was repressed at T 3o, but after 120 min each of these 
genes and plcA were repressed. In contracts , addition of RLs induced hlyA expression 
after 120 min . Down-regulation of these genes would make L. monocytogenes EGDe less 
virulent with extended exposure by repressing the binding proteins and impairing the 
capacity for intracellular survival as well (20). 
Conclusion 
Treatment of L monocytogenes EGDe with sub-MIC doses of SP 25A and RLs 
led to complete inhibition of growth or a reduction of growth, respectively . However , this 
inhibition was uncoupled from membrane perrneabilization in the case of SP 25A. The 
gene expression profile of cells treated with SP 25A revealed that genes related to cell 
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division, chromosome replication, intermediatery metabolism , transcription, translation , 
and virulence were repressed. These effects were not produced in cells treated with RLs. 
These observations indicate that SP 25A permeabilizes the membrane , but the 
mechanisms associated with cell death are likely related to other targets that inhibit cell 
division ; while, the antibacteria l activity of RLs is likely due to its interaction with the 
membrane. 
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Table 4.1. Functional categories that contained the genes that were significantly 
differentially expressed in response to treatment with sub-MIC doses of RLs . 
No. of differentially expressed genes 
Total 
Functional category genes 111 T30 Tl20 
category 
Induced Repressed Induced Repressed 
A BC transporters 134 0 0 2 I 
Ion channels 4 0 0 0 0 
PEP/PTS components 80 0 0 3 0 
Polysaccharide degradation 18 0 0 I 0 
Central intermediate,)' metabolism 272 0 I 4 0 
Cofactor and coenzyme metabo lism 116 0 0 0 0 
Amino ac id metabolism 179 0 0 2 0 
Electron transport and oxidative 61 0 0 phosphmylation 
Cell wall metabolism 57 0 0 0 0 
Transcription regulators 142 I 0 2 0 
Transcription 36 0 0 0 0 
Protein biosynthesis 158 0 I 
Protein fate 92 0 I 0 
Secretion 63 0 0 0 
Virulence factors 131 0 0 I 0 
Stress 50 0 0 2 0 
Ce ll division 17 0 0 0 0 
Phage protein s 18 I 0 0 2 
Unknown /Hypoth etical proteins 4 0 7 2 
Total 1628 8 2 27 7 
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Table 4.2. Significantly differentially regulated genes during exposure to RLs. 
Log2 Ratios 
Protein ORF Cellular Role Q 
T30 T120 
value 
ABC transporter (Metal binding protein) LM01073 A BC transporter s -0.18 0.97 0.26 
ABC transporter (ATP-bind ing protein) LM02 l 93 A BC transporters 0.33 0.32 O. ll 
A BC transporter-associated protein, sufB LM024l I ABC transporters -0.43 -0.17 0.23 
Fructose-specific phosphotransferase LM00399 PEP/PTS components 
enzyme IIB 
0.21 0.38 0.11 
Fructose-specific phosphotransferase LM00400 PEP/PTS components 
enzyme ITC 
0.05 2.54 0.11 
Beta-glucoside-specific enzyme TIABC LM00738 PEP/PTS components 0.46 1.36 0.11 
component 
Alpha mannosidase LM00401 Polysaccharide -0. 15 2.70 0. 11 degradation 
Ribose 5-phosphate isomerase LM00736 
[ntermediatery 
-0.03 1.72 0.11 
metabolism 
6-phospho-beta-glucos idase LM00739 lntermediatery 0.04 2.86 0.1 I 
metabolism 
Pyruvate dehydrogensae ( dihydrolipoamide LMOI055 Intermediatery 0.24 0.96 0.11 dehydrogenase , E3 subunit) , pdhD metabolism 
Phosphoglyceromutase LM02205 Intermediatery -0.73 0.86 0.15 
metabolism 
Ribulose-phosphate 3-epimerase LM0 2659 lntermediatery 0.0 I 1.70 0. I I 
metabolism 
G Jyc ine dehydrogenase ( decarboxylating) LM01350 Aminoacid -0.4 I 1.21 0. I I 
subunit 2 metaboloism 
Threonine 3-dehydrogenase LM02663 Aminoacid -0.06 1.98 O. l I 
metaboloism 
H+-transporting ATP synthase C chain, Respiration and LM02534 oxidative 1.64 - I .81 0.11 
atpE phsphorylation 
Peroxide operon regulator, perR LMOJ683 Transcription regulator -0.13 1.03 0.11 
Transcriptional regulatory protein degU LM02515 Transcription regulator 0.12 1.39 0.16 
Phenylalanyl-tRNA synthetase alpha chain, LMOl221 Protein biosynthesis 0.62 -0.45 0.29 
pheS 
Acetyltransferase LM00624 Post translational -0.62 I.OJ 0.29 
modification 
ATP-depe ndent endopeptidase clp ATP- LM00997 Protein degradation -0.03 1.28 0. I I binding subunit, clpE 
Oxidoreducatse involved in TA Tpathway LM00737 Secretion 0.05 1.02 0. I I 
secreted proteins 
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I isteriolysin O precursor , hfy LM00202 Virulence 0 .24 1.90 0.11 
Single-stranded DNA-binding protein, ssb LM00045 Stress -0.01 1.33 0.11 
Cold shock protein, cspL LMOl364 Stress 0.14 0.45 0.29 
Non-heme iron-bindin g ferritin ,.fi'i LM00943 Stress 0.09 0.81 0.11 
Phage proteins LM02287 Phage proteins 0.66 -0 .58 0.11 
Phage proteins LM02327 Phage proteins 0.27 -0 .6 1 0.11 
Hypothetical Protein LM00743 Unknown 0.12 0.82 0.15 
Hypothetical Protein LM01113 Unknown 0.77 -0.39 0.11 
Hypothetical Protein LM02257 Unknown 0.00 0.94 0.1! 
Hypothetical Protein LM02432 Unknown -0.20 3.24 0. 11 
Stage V sporulation protein G LMOOl97 Others 0.86 -0. 61 0.11 
Rhodanese-related sulfurtransferases LM01384 Others 0.60 -0.48 0.11 
Glycerol uptake facilitator protein LMOl539 Others 0 .21 0.82 0.14 
Creatinine amidohydrolase family protein LM01968 Others 0.77 -0.56 0. 11 
Protease I LM02256 Others 0.17 0.99 0.26 
Putative tran scr iptional regulator, McrR LM02728 Others -0.05 0.63 0.15 family 
Putative transcriptional regulator , MerR LM02334 Others 0.57 -0 .66 0.15 family 
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Table 4.3. Functional categories that contained the genes that were significantly 
differentially expressed in response to treatment with sub-MIC doses of SP 25A. 
Number of differentially expressed genes 
Total 
Functional category genes m T30 T120 
category 
Induced Repressed Induced Repressed 
ABC transporters 134 3 2 8 
Ton channels 4 0 0 
PEP/PTS components 80 0 4 0 4 
Polysaccharide degradation 18 0 0 I 
Central intermediatery metabolism 272 2 13 0 24 
Cofactor and coenzyme metabolism 116 0 4 0 5 
Amino acid metabo lism 179 0 0 4 
Electron transport and oxidative 61 0 4 0 5 phosphorylation 
Cell wall metabolism 57 0 I 0 2 
Transcription regulator s 142 I 0 I 4 
Transcription 36 0 0 0 3 
Protein biosynthesis 158 2 3 0 12 
Protein fate 92 0 ,, 0 4 .) 
Secretion 63 I 2 0 3 
Virulence factors 13 I 2 I 0 4 
Stress 50 4 5 0 13 
Cell division 17 0 2 0 4 
Phage proteins 18 0 0 0 0 
Unknown /Hypothetical proteins 12 13 2 34 
Total 1628 26 60 5 135 
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Table 4.4. Significantly differentially regulated genes during exposure to SP 25A. 
Log 2 Ratios 
Protein ORF Cellu lar Role Q T30 T120 
value 
Manganese uptake Mn ABC transporter LM01847 A BC transporters 0.66 -3.85 0 .00 
Metal cations ABC transporter , permease LMOl848 A BC transporters -3.43 -2.43 0.00 protein 
ABC transporter, ATP-binding protein LM02415 A BC transporters -0.47 -0.65 0.00 
Heavy metal-transporting A TPase LM00641 A BC transporters -0.45 -0.42 0.01 
Manganese transport proteins NRA MP LM01424 A BC transporters -2.10 0.01 0.01 
Metal cations ABC transporter, ATP- LM01849 A BC transporte rs -0.89 -0 .78 0.04 binding proteins 
A BC transporter-associated protein LM0241 I A BC transporters -0 .51 -0.20 0.04 (suffi) 
Oligopeptide ABC transporter (ATP- LM02193 ABC transporters -0.24 -0.46 0.17 binding protein) 
Acetoin uptake permease protein LM02239 ABC transport ers -0.24 0.68 0.17 
ABC transporter (ATP-binding protein) LM02 139 ABC transporters 0.07 0.60 0.23 
Large conductance mechanosensitive LM02064 Ton Channel 1.96 -2.70 0.00 
channe l 
Fructose-specific phosphotran sferase LM00400 PEP/PTS components -1.78 -0 .34 0.00 
enzyme rrc 
Beta-glucoside-specific enzyme llA BC 
component LM02373 PEP/PTS compone nts 0.39 -0.83 0.00 
Beta-glucoside-specific enzyme !IA BC LM00738 PEP/PTS components -1.04 -1.04 0.00 
component 
Trehalose specific enzyme lIBC LMOl255 PEP/PTS components -3.74 -0.40 0.00 
Alpha mannosidase LM00401 Polysaccharide -2 .6 1 -0.78 0.00 degradation 
6-phospho-beta-glucosidase LM00739 I ntermediatery 0.97 -2.39 0.00 
metabolism 
6-phospho-beta-glucosidase LM00536 lntermediate1y -038 -0.24 0.23 
metabolism 
A lpha ,alpha-ph osphotrehalase LMOl254 lntermediate,y -2.10 -0.04 0.00 
metabolism 
Pyruvate dehydro genase (EI alpha LMOI052 Tntermediate1y -2.74 -0.38 0.00 
subunit), pdhA metabolism 
Pyruvate dehydrogenase (EI beta LMOI053 Intermediatery -3 .04 - l.38 0.00 
subunit), pdhB metabolism 
Pyruvate dehydrogenase LM01054 Intermediatery -2 .04 -2.62 0.00 (dihydrolipoamide acetyltransferase E2 metabolism 
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subunit), pdhC 
Pyruvate dehydrogensae ( 
lntermediatery dihydrolipoamide dehydrogenase, E3 LM01055 -2.58 -2.31 0.00 
subunit), pdhD metabolism 
L-lactate dehydrogenase , ldh LMOI057 fntermediatery - I. 11 -0.52 0.04 
metabolism 
Pyruvate kinases, pyk.A LMOl570 r ntermediatery -0.60 0.38 0.03 
metabolism 
Ribose 5-phosphate isomerase LM00736 lntermediatery -0.81 -0.32 0.00 
metabolism 
Ribulose-5-Phosphate 3-Epimerase LM00735 Intermediatery -0.43 -0.48 0 00 
metabolism 
Transaldolase LM02743 lntermediatery -0.62 -0.13 0.29 
metabolism 
Fructose-1,6-bisphosphate aldolase ,.fbaA LM02556 r ntermediatery -0.22 -0.38 0.07 
metabolism 
Dihydroxyacetone kinase LM02695 Intermediatery -0.49 -0.71 0.03 
metabolism 
Dihydroxyacetone kina se LM02696 Intermediatery -0.51 -0.81 0 .00 
metabolism 
Dihydroxyacetone kinase 
LM02697 Intermediatery 0.41 -1.51 0.01 phosphotransfer protein metabolism 
Glucosam ine-6-Ph oasp hat e isomerase LM00957 lntermediatery -0.52 -0.31 0.07 
metabolism 
L-gl utam ine-0- fructose-6-phosphate LM00727 lntermediater y 0.76 -2.90 0.00 
amidotransferase metabolism 
Phosphoglyceromutase LM02205 fntermediatery -0.21 -0.42 0.03 
metabolism 
Branched-chain alpha-keto acid 
dehydrogenase E2 subunit (lipoamide LMOl374 Amino acid metabolism -0.56 -0.11 0.03 
acy ltran sferase) 
G lycerate dehydrogenases LMOI684 Amino acid metabolism -1.26 -1.22 0.00 
Glyc ine dehydrogenase ( deca rboxylating ) LM01350 Amino acid metabolism -0 .34 -1.68 0.00 
subunit 2 
A Ian ine dehydrogenase LMOl579 Amino acid metabolism -0.38 -0.25 0.00 
IscU protein LM02412 Cofactor-coenzyme -1 .39 -1.00 0.00 
metabolism 
Cysteine desulfurase LM024 13 Cofactor-coe nzym e -2.04 -0.40 0.10 
metabolism 
SufD protein LM02414 Cofactor-coenzyme -1 .50 -0.94 0.00 
metabolism 
Pyridoxine biosynthesis protein LM02101 Cofactor -coenzyme -1.82 -0.40 0.00 
metabolism 
Pyridoxine biosynthesis amidotransferase LM02102 Cofa ctor-coenzyme -0 . 15 -0.83 0.00 
metabolism 
AA3-600 quinol oxidase subunit I LMOOOl4 Respiration and -0 .91 -0 09 0. I 0 
oxidative phsphorylation 
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AA3-600 quinol oxidase subunit JJJ LMOOOl 5 Respiration and -0 .73 -0.50 0.03 
oxidative phsphorylation 
AA3-600 quinol oxidase subunit IV LMOOOl6 Respiration and -0.52 -0.37 0.17 
oxidative phsphorylation 
H+-transporting ATP synthase chain LM02531 Respiration and -0.58 0 . 11 0 .29 
alpha, atpA oxidative phsphorylation 
H+-transporting ATP synthase C chain , LM02534 Respiration and -1.14 0 .32 0.00 
atpE oxidative phsphorylation 
UDP-N-acetylglucosamine 1- LM02526 Cell wall metabolism - I. l 0 -0 .21 0.00 
carboxyvinyltransferase , murA 
Peptidoglycan anchored protein (LPXTG LM02714 Cell wall metabolism -0 .03 -0.98 0 .00 
motif) 
Transcriptional regulator , MarR family LM00266 Transcription regulator -0.25 0 .89 0.29 
Transcriptional regulator , MarR family LM02200 Transcription regulator 0.62 -2 .07 0 .00 
Transcriptional regulator , Ly tR family LM00433 Transcription regulator -0.5 3 -0.80 0.01 
Heat-inducible transcription repressor , LMOl475 Tran scription regulator -0 .56 -0.16 0.00 hrcA 
Peroxide operon regulator , p erR LMOl683 Tran scription regulator 0.28 -2.71 0 .00 
Negative regulator of genetic competence LM02190 Transcription regulator 0.24 -0.62 0.02 
mecA 
RNA polymerase (alpha subunit),1p oA LM02606 Transcription -0.3 I -0 .30 0.01 
RNA polymerase (beta subunit),rpoB LM00258 Transcription -0.47 -0.76 0.02 
RNA polymerase (beta' subunit) , rpoC LM00259 Transcription -0.12 -0.46 0 .00 
Ribosomal protein S6, 1psF LM00044 Protein biosynthesi s -0.47 -0.70 0.00 
Ribosomal protein S 18, rpsR LM00046 Protein biosynthe sis 0. 15 -0.67 0.00 
Ribosomal protein S2 l , rpsU LMOl468 Protein biosynthesis 1.37 -2 .22 0.00 
Ribosomal protein L 16, rp!P LM02625 Protein biosynthesis -0 .16 -0.56 0.00 
Ribosomal protein L2, rp!B LM02629 Protein biosynthesis -0 .52 -0.29 0.00 
Ribosomal protein S2, rpsB LMOI658 Protein biosynthesis -0.26 -1.04 0.02 
Ribosomal protein L27 , rpmA LMOJ540 Protein biosynthesis -0.2 I -0.60 0.03 
Hypothetical ribosome-associated protein LMOl54l Protein biosynthesis 0.00 -0.59 0.03 
Ribosomal protein L 15, rplO LM02613 Protein biosynthesis -0.62 0.06 0.23 
83 
Ribosomal protein L23 , rp/W LM02630 Protein biosynthes is -0 .38 -0.19 0.29 
Translation elongation factor G LMO Protein biosynthesis -1.00 -0.35 0.02 2654 
Translation elongation factor EF-Tu LMO Protein biosynthesis -2.50 -1.13 0.00 2653 
Ribosomal-protein-alanine LMOl301 Protein biosynthesis -0 . 18 -0.40 0.23 
acetyltransferase 
Ribosome associated factor Y (global LM02511 Protein biosynthesi s 1.41 -3 .85 0 .00 translation inhibitor) 
A cety ltransferase LM00624 Post translational 0.39 -0.82 0.00 
modification 
ATP-dependent endopeptida se clp ATP- LM00997 Protein degradation -0.70 -1.23 0.00 binding subunit , clpE 
ATP-dependent endopeptidase clp ATP- LMOl268 Protein degradation -0.78 -0.41 0.17 binding subunit , clpX 
ATP-dependent clp endopeptidase Clp LM02206 Protein degradation -0 .72 -0.07 0.10 ATP-binding chain B, ClpB 
Oxidoreducatse involved in TATpathway LM00737 Secretion 0.61 -2.64 0.00 
secreted proteins 
60 kDa inner membrane protein yid C LM0!379 Secretion -0 .59 -0.57 0.00 
Protein translocase subunit sec Y LM02612 Secretion -0.79 -0.03 0.02 
1-phosphatidylinositol phosphodiesterase LM00201 Virulence -0.33 -0.92 0.00 precursor , plcA 
listeriolysin O precursor, hly LM00202 Virulence 1.31 -2.70 0.00 
Invasion associated protein , iap LM00582 Virulence -0 .99 -0.58 0.00 
Fibronectin-binding protein LM00721 Virulence 0.76 -1.44 0.00 
General stres s protein LMOl601 Stress 0.16 -0.73 0.00 
Universal stress protein family LMOl580 Stress 0.66 -0.19 0.00 
Toxic ion resistance proteins LMOl967 Stress -0.74 -0.29 0.00 
Arsenate reductase LM02230 Stress 0.59 -1.03 0.00 
Superoxide dismutase , sod LMOl439 Stress -1.39 -4.35 0.00 
Non-heme iron-binding ferritin ,_Fi LM00943 Stress 1.23 -3 .65 0 00 
Peptide methionine sulfoxide reductase s, LMOl860 Stress -1 .68 -0.25 0.00 
msrA 
Peptide methionine sulfoxide reductase, LMOl859 Stress 0.19 -0 .90 0.00 
msrB 
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Organic hydroperoxide resistance 
LM02199 Stress 0.79 -1.51 0.00 protein 
Thioredoxin reductase, lrxB LM02478 Stress -1.61 -0.63 0.00 
Heat shock protein , grpE LMOl474 Stress -0 .87 -0.03 0.04 
Class I heat-shock protein (chaperonin), LM02068 Stress -0.88 -0.44 0 .03 groEL 
Single-stra nded DNA-binding protein , LM00045 Stress 0.53 -3.84 0.00 
ssb 
Excinuclease ABC (subunit A), uvrA LM02488 Stress -0.53 -0 .84 0.04 
Endonuclease involved in recombination LMOJ502 Stress /Cell division -0.4 8 -0.86 0.03 
DNA gyrase subunit B, gyrB LM00006 Cell division -0.85 -0.29 0.00 
DNA gyrase subunit A, gyrA LM00007 Cell division -0 .5 1 -0. 14 0.02 
A TPase associated with chromosome 
LM02759 Ce ll division 0.46 -0.77 0 00 
arc hitecture /replic ation 
Ce ll division initiation protein DivlVA LMOl888 Ce ll d ivis ion -0.65 -0.28 0.03 
Hypothetical Protein LM00377 Unknown -0 08 -0 .73 0.00 
Hypothetical Protein LM00393 Unknown 0.87 -0 .95 0.00 
Hypothetical Protein LM00647 Unknown 1.00 -2.42 0.00 
Hypothetical Protein LMOl380 Unknown -0.63 -0.07 0.00 
Hypothetical Protein LMOl423 Unk11own -1 .04 - 1.28 0.00 
Hypothetical Protein LMO l612 Unknown 1.20 -1.69 0.00 
Hypothetical Protein LM02257 Unknown 0.74 -0 .75 0.00 
Hypothetical Protein LM02432 Unknown 3.52 -3.23 0.00 
Hypothetical Protein LM02828 Unknown 0.79 -1.05 0.00 
Hypothetical Protein LM02156 Unknown 0.72 -0.88 0.01 
Hypothetical Protein LMO l8 93 Unknown -0 .06 -0 .5 1 0.03 
Hypothetical Protein LMOl980 Unknown 0.58 -0.39 0.07 
Hypothetical membrane spanning protein LM00625 Unknown 0.12 -1.29 0.00 
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Hypothetical membrane spanning protein LM00653 Unknown -0.52 -0.31 0.01 
Hypothetical membrane associated LM02119 Unknown -0.62 -0 .54 0 .00 protein 
Hypothetical membrane spanning protein LMOl690 Unknown -1.04 -0 .63 0.00 
GatB/ Yqey domain protein LMOl468 Unknown 0.25 -0.92 0.00 
Hypothetical cytosolic protein LMOl501 Unknown 0.05 -1.45 0 .00 
Hypothetical cytosol ic protein LM02472 Unknown -0.58 0.21 0 .00 
Hypothetical cytosolic protein LM00964 Unknown -3.18 -0.84 0.00 
Cytosolic protein containing multiple LMOl576 Unknown - I. 18 -0.16 0.00 CBS domains 
Stage V sporulation protein G LMOOl97 Others -0.38 -0 .31 0.23 
Stage V sporulation protein G LMOOl96 Others -0 .72 -0.27 0.23 
Acetyl esterase LM02089 Others -0.30 -1.19 0.00 
Protease I LM02256 Others 0.83 -2 .28 0.00 
Glyoxalase family prot ein LM02437 Others 2.91 -4.22 0.00 
Predicted hydro lases or acyltransferases LM02453 Others -0.80 0.13 0.10 (alpha/beta hydrolase superfarnily) 
Hydrolase (HAD superfamily) LMOl399 Others -0 .87 -0.38 0.17 
Putative transcriptional regulator, AraC 
LMOOI09 Others -0.50 -0.14 0. 10 family 
Putative ranscriptional regulator , ArsR LMOOIOI Others -0 .30 0 .58 0.03 family 
Putative tran scription regulator LM00740 Others 0.13 0.76 0.29 
Phosphoesterase, DHH family protein LMOl575 Others -0 .56 -0 .37 0.00 
Carboxylesterase LM02452 Others -0.92 0.03 0.00 
Glycerol uptake facilitator protein LMOl539 Ot hers -0.56 -0.37 0.07 
Permease LM02148 Others 0.15 0.64 0. 17 
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Fig 4.1. Membran e permeabili zation determined by the increase in fluorescence (RFU) 
with PI uptake during treatment of L. monocyto genes with SP 25A and RLs (A), and cell 
growth when treated with SP 25A, RLs and saline (control) over a period of 120 min (B). 
CHAPTER 5 
SUMMARY 
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Development of antibiotic resistance in bacteria is one of the most troublesome 
issues facing health sciences today. There is no certain way to circumvent this problem , 
but discovery and development of novel compounds that inhibit bacteria by different 
mechanisms is required on a consistent basis. Secondary metabolites from 
microorganisms have been the most abundant source of new antimicrobials in the past. 
This study used two secondar y metabolites from fluorescent pseudomonads , 
syringopeptin 25A (SP 25A) and rhamnolipids (RLs) , a lipodepsipeptide and a surfactant, 
respectively , to determine the potential for their use as antimicrobial agents. 
Several criteria must be met before a compound can be added to the arsenal of 
antibiotics in daily use: 1) the range of activity against bacteria must be known , 2) the 
MIC must be low enough to permit active doses that are not toxic , 3) an estimation of the 
mechanism of action must be determined , 4) the pharmacokinetics of the compound fate 
must be known, and 5) the compound must be approved for human use. This study 
focused on the first three criteria as a measure of the need to pursue criteria four and five. 
Both the compounds, though from different chemical classes , are thought to act 
on the bacterial cell membrane to cause cell lysis and death . RLs have a very low critical 
micelle concentration (1-1 Oµg/ml) and are thought to have a detergent-like action on the 
bacterial cell membrane causing it to dissolve (2). SP 25A, and syringopeptins generally , 
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on the other hand is thought to form transmembrane pores in the cell membrane; thereby , 
disrupting the permeability barrier of the bacteria ultimately leading to lysis ( 4, 7). 
Previous studies with these compounds showed that they inhibit a number of bacteria , but 
the range of organisms used was somewhat limited (1, 2, 5, 6). However , an ever-
increasing data set is emerging that is challenging these models for antimicrobial action. 
These studies screened a large number of diverse bacteria and mold to determine the 
activity range of these two compounds , subsequently, used gene expression arrays during 
exposure of Listeria monocytogenes to sub-M IC doses of these compounds to determine 
non-membrane targets associated with growth inhibition. 
Hypothesis 
Syringopeptin 25A (SP 25A) and rhamnolipids (RLs) inhibit many bacterial 
species by disrupting the cellular membrane . 
Objectives 
1. Screen candidate compounds for microbial inhibition and determine the minimum 
inhibitory concentration for these compounds against selected bacteria 
2. Determine the cellular responses to sub-MIC levels of SP 25A and RLs using 
gene express10n arrays. 
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To screen the antimicrobial potential of these compounds they were tested against 27 
different organisms , which included Gram-positive and Gram-negative bacteria and mold 
that are multiple drug resistant human pathogens, food spoilage organisms, bacterial 
spores, and fermentative bacteria . The initial screening was done using a rapid technique 
to determine the membrane permeabilization with a fluorescent DNA-binding dye that is 
blocked from entering the cell by an intact membrane. Subsequently, the MIC for each 
compound with each inhibited organism. Both the compounds inhibited growth of all the 
Gram-positive organisms . Mycobacterium smegmatis, the surrogate test organisms for 
Mycobacterium tuberculosis, was also inhibited. SP 25A also inhibited the. Interestingly , 
SP 25A inhibited two multiple antibiotic resistant strains of Staphylococcus aureus and 
Enterococcus faecalis and spore germination of bacterial spores. For all the organisms 
tested SP 25A showed similarly lower MIC values as compared to RLs with a range from 
3 µg/ml to 16 µg/ml; reasonable concentrations for therapeutic use . 
While the MICs were reasonable , we sought to reduce it further by combining the 
compounds to determine if they were synergistic in their activity. We demonstrated a 
synergistic activity against Listeria monocytogenes , which allowed the concentration of 
SP 25A to be reduced to below the MIC level , yet increase the cellular inhibition Neither 
compound was toxic to three mammalian cell lines at the concentration of the effective 
MICs. Hence , taking into account the lower MICs, anti-spore activity, antimycobacterial 
activity, inhibition of multiple antibiotic resistant strains and no toxicity to mammalian 
cell lines SP 25A appears to be a promising therapeutic agent. 
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During the course of this study we observed a lack of correlation between 
membrane permeabilization and growth inhibition for SP 25A. When L. monocytogenes 
was challenged with sub-MIC doses of both the compounds, RLs induced PI uptake 
while SP 25A did not , yet it completely inhibited cell growth. A number of other groups 
have also observed that membrane-active antimicrobial peptides exert effects on cell 
growth beyond their ability to interact with the membrane (3, 8). This apparent lack of 
correlation between membrane permeabilization and inhibition of cell growth led us to 
suspect that the pore forming model alone may not be responsible for all of the 
antimicrobial properties of SP 25A. Therefore, we hypothesized that SP 25A represses 
gene expression to cause growth inhibition . To test this we challenged L. monocytogenes 
with sub-MIC concentrations of SP 25A and RLs and monitored gene expression profiles 
before treatment with antimicrobials , 30 min after treatment , and 120 min after treatment 
using a custom commercial high-density, whole genome oligonucleotide arrays (Chapter 
4) . 
The gene expression profile was distinct between the two antimicrobials. SP 25A 
repressed genes required for cell division , chromosome replication and segregation, 
intermediary metabolism , transcription , translation , and virulence genes. Conversely, RLs 
induced a broad set of genes that were related to energy production. Hence , these data 
indicate that even though both the antimicrobials may interact with a conunon cellular 
structure (i.e. the cell membrane) their mode of action is different, with SP 25A having 
little ability to damage the membrane, but substantial ability to inhibit production of 
proteins critical to cellular replication . This supports the concept that antimicrobial 
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peptides do not entirely rely upon their membrane permeabilizing ability to exert their 
anti bacterial action . This study brings forth SP 25A as a promising therapeutic agent that 
has a unique cellular target (e.g. Div IVA) to inhibit cell growth of a pathogenic bacterium 
at a reasonable MIC. 
Future work with this compound needs to demonstrate the other criteria for 
antibiotics. Additional work needs to be done to assess the antimycobacterial potential 
and the efficacy in vivo for the inhibition of other Gram-positive pathogens. 
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COMPOUND PURITY 
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Fig A 1. Massspectrogram of SP 25A purified from Pseudomonas syringae pv syringae Ml cultures . 
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Fig A2. 13C NMR spectra of RL mixtur e obtained from Jeniel Biotech. 
APPENDIXB 
VALIDA TI ON OF PI ASSAY 
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Fig B 1. Mean PI uptake by L. lactis IL1403 treated with saline (negative control for the 
PI assay) over a period of 120 min. 
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APPENDIXC 
R CODE F'OR DAT A NORMALIZATION 
Code For RMA Normalization In R Of Raw 
Data Received From NimbleGen Systems: 
Library (affy) 
Data=read. table(" lmono . txt" ,nrows=400000,sep="\t" ,check.names=false,header=true) 
Corrected.data<-apply( as.matrix( data[,3: 14 ]),2,bg.adjust) 
Normalized. data <-normalize . quantiles( corrected. data) 
Probe.data <-cbind( data[ , 1 :2],normalized.data) 
Expression.data<-data.frame() 
Seq.ids <-unique(a s.vector(probe.data$seq_id)) 
Express ion .data <-data.frame() 
For (seq.id in seq.ids) { probes <-
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new("probeset" ,id=seq .id,pm =as.matrix(subset(probe.data[ ,3: 14] ,probe.data$seq_id ==se 
q.id))) 
Ev= express.summary .stat(probes ,summary="medianpolish" ,pmcorrect="pmonly ") 
Expression.data<-rbind( expression.data ,t( ev$exprs )) 
} 
Expression.data<-as . data. frame( cbind( seq .ids,expression.data)) 
Names( expression.data) <-names( data)[ c( 1,3: 15)] 
write. table( expression.data,file=" nfile . txt" ,col.names=na ,quote=f ,sep="\t") 
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APPENDIXD. 
HEATMAPS OF EXPRESSION DAT A 
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